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Compounds containing hydroxamate moieties (N-hydroxyl amides) in their structure have found 
a vast range of therapeutic applications such as antibacterial, anti-tumour, anti-immune 
suppressor, and for iron overloading treatment. Hydroxamate chelators binds to Fe (III) tightly 
through its electron donating oxygens. The binding strength is maximized in compounds 
containing three hydroxamic moieties due to the so called “chelate effect”. As all microorganisms 
require iron for surviving, they develop endogenous siderophores to acquire iron from the 
surroundings. Siderophores contain hydroxamate, catecholates, α-hydroxy carboxylates groups, 
among others, in their structures. The acquisition of iron by siderophores in microorganisms goes 
through specific cycles that includes sequestration of Fe(III), recognition and uptake of the ferri-
siderophore through the cell membrane, and then release of the iron in the cytoplasm. 
Many natural hydroxamate siderophores contain a peptidyl backbone. In this work, peptides 
containing one or more units of 1,2-hydroxypyridine-N-oxide (1,2-HOPO) have been 
synthesized.  The introduction of these units on the peptides has been done by means of 4-
carboxy-1-hydroxypyridil-2-one (1,2-HOPO-4-COOH) using solid-phase peptides synthesis 
(SPPS) protocols. The obtention of the new “siderophores” containing three 1,2-HOPO units 
have been done by two different approaches, sequential and convergent. The compounds have 
been evaluated as potential iron chelators. Thus, the pKa values and the thermodynamic constants 
of all ligands have been spectrophotometrically determined. The Fe(III) affinities of the two 
hexadentate ligands  (ligand B and ligand C) have been determined by competition experiments 
against EDTA. The results showed that the iron complex ligand B is stronger that the iron 
complex EDTA since the last is not be able to replace it. Hence, this new siderophore could be a 
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Aim and objectives 
The aim of this work is to develop a simple method to obtain peptides bearing hydroxamic acid 
through the linkage of 1,2-hydroxypyridine-N-oxide (1,2-HOPO) moieties to be used as iron 
chelators (ligands). To achieve this aim, the following objectives have been proposed: 
1. Study the best conditions to introduce 4-carboxy-1-hydroxypyridil-2-one (1,2-HOPO-4-
COOH) in a peptide sequence using solid-phase peptide synthesis (SPPS) protocols. 
1.a. Unprotected strategy. 
1.b. Benzyl protection of N-hydroxyl function. Removal of the protecting group at the 
end of the synthesis 
2. Optimization of the synthesis of peptides with multiple HOPO containing moieties: 
sequential vs convergent approaches. 
3. Spectrophotometric determination of the pKa’s of the new bidentate and hexadentate 
ligands. Comparison with the unconjugated moieties: 1,2-HOPO-4-CONH2. 
4. Study of iron complexation of the different ligands: stoichiometric ratios and stability 
constants determination (βMLH). 





An introduction to the use of hydroxamate siderophores as trojan horses is provided in Chapter 
1. An efficient method for synthesis of HOPO-containing peptides on solid phase support is 
introduced in Chapter 2. A detailed protocol for the SPPS method used to prepare HOPO- 
containing peptides in included in Chapter 3. A thermodynamic evaluation of four new ligands 
and their Fe (III) complexes using spectrophotometric methods is reported and discussed in 
Chapter 4. FDA-approved “Tides” (peptides and oligonucleotides) in the last three years are 
discussed in Chapters 5-7. Two of the drugs approved ([177Lu] Lu-DOTATATE in 2018 and 
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Hydroxamic acids are an important class of molecules, in particular because of their metal-chelating
ability. Microorganisms, including pathogenic bacteria, use hydroxamate-based entities (siderophores),
among others, to acquire Fe (III). The “Trojan horse” strategy exploits the need of bacteria for this metal
by using Fe (III) active transporters to carry antibacterial or bactericidal moieties into the bacterial cell.
Many natural Trojan horses (sideromycins) are derived from hydroxamic acids, thereby reflecting their
potency. Various artificial sideromycins and their antibacterial activities have been reported. This review
discusses the structural aspects of the hydroxamate-siderophores isolated in the last two decades, the
chemical synthesis of their building blocks, their binding affinity towards Fe (III), and their application as
Trojan horses (weaknesses and strengths).
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D. Al Shaer et al. / European Journal of Medicinal Chemistry 208 (2020) 11279121. Introduction cell wall [16].Iron is an essential nutrient for most living organisms [1].
Although accounting for about 35% of Earth’s mass [2], its
bioavailability tomicroorganisms is limited. This is attributed to the
fact that under anaerobic conditions, iron is present as Fe (III),
which in aqueous media is either precipitated out (trapped) as
insoluble hydroxides (Ksp ¼ 1018 M) or is bound to host proteins
such as transferrin, ferritin and lactoferrin leaving the free Fe (III) at
concentrations as low as 1  1024 M [1,3].
To acquire iron in iron-deficient environments, microorganisms
(such as bacteria and fungi) produce “Siderophores” [1,4], the Greek
term meaning iron carriers. Siderophores have specific and high
affinity towards iron, thus allowing microorganisms to scavenge
this coveted nutrient from their environment and ensure their
survival.
Fe (III) forms octahedral complexes with six electron-donating
atoms symmetrically spatially distributed around the central iron.
Maximum binding affinity is achieved when all six atoms inter-
acting with iron are present in the same molecule, thus empha-
sizing the “chelate effect” in the multiple denticity. Natural
siderophores are mostly hexadentates, in which the binding units
vary between catecholates, a-hydroxy carboxylates, hydroxamates
and a mixture of these functional groups [5] (Fig. 1).
The microbial iron uptake cycle starts with the production and
secretion of “endogenous” siderophores (those produced by the cell
itself) into the surroundings. These siderophores solubilize Fe(III)
from its hydroxide or capture it from host proteins [6]. Ferrisider-
ophores (siderophore-Fe(III) complexes) are usually more than
500 Da, which means that they require certain transport systems to
transfer them into the cell. Specific membrane (outer membrane in
gram-negative bacteria) protein receptors recognize the complex
via key features [6,7]. Recognition triggers the transport system and
subsequent uptake occurs. Some outer membrane protein re-
ceptors are binding unit-specific and can recognize a wide spec-
trum of siderophores with same type of chelating units, such as
FhuA (ferric hydroxamate outer membrane receptor) and FecA
(ferric citrate). This capacity allows some species to use the side-
rophores produced by other organisms (xenosiderophores) [8].
Other receptors are specific for only a given siderophore, such as
FptA (ferric pyochelin transport) and FpvA (ferric pyoverdin) [9].
Although outer membrane receptors for ferrisiderophore
mediate the nourishment (feeding) of the cell, they can also poison
it. Some microorganisms hybridize the siderophore with a bacte-
ricidal moiety (sideromycin ¼ sideophore þ antibiotic) to attack
other species and kill them. This microbial strategy (Trojan horse)
has inspired the research community to develop a new approach to
increase the permeability of the drug into the multi-drug resistant
cell [10e12]. In this regard, increasing bacterial resistance to almost
all known antibiotics has come about from the overuse of antibi-
otics for the treatment of bacterial infections [13,14]. The discovery
of only a handful of novel antibiotics over the last few decades has
made it necessary to devise innovative strategies to combat path-
ogenic bacteria [15], the Trojan horse strategy emerging as a
promising approach.
Among the five known families of natural sideromycins, three-
dalbomycins, ferrimycins and salmycinsduse the hydroxamate
binding moiety (the other two families are salmochelim and
microcin). Albomycins (3, Fig. 2) are themost widely known natural
sideromycins and they have a proven efficiency against many or-
ganisms with the FhuA receptor in their outer membrane (see
section 2.4.1.1). This activity emphasises the role of this family of
chelators in overcoming the permeability barriers of the microbial9
In this review we discuss hydroxamate siderophores in terms of
their natural occurrence, chemical synthesis, binding affinity to-
wards Fe(III) and potency as antimicrobial drug conjugates.2. Hydroxamate-based siderophores
Hydroxamic acids have the general formula RC(O)N(OH)R’. They
can be defined asN-hydroxy amides. This structure gives the proton
of the hydroxyl some acidic properties depending on the solvent,
with pKa values of about 9 [17]. When deprotonated, hydroxamate
ion can strongly bind to various positively charged metal ions
(Fig. 2). In a wide spectrum of natural siderophores, the chelating
unit of hydroxamic acid is found either within the backbone or as
pendants (Fig. 2).2.1. Natural occurrence of hydroxamate siderophores
Hydroxamate siderophores are produced mainly by fungi and
some strains of bacteria. The first known families were ferrichrome
(1, Fig. 2), which was isolated from smut fungus Ustilago sphaer-
ogana [18], and coprogen (5) [19], both isolated and reported in
1952. The structure of ferrichrome was characterized later in 1960
[20]. Another hydroxamate siderophore is desferrioxamine B (DFO
B,6), the most famous member of the ferrioxamine family. Nobel
laureate Vladimir Prelog and co-workers isolated DFO B from
Streptomyces pilosus and first reported it in 1960 [21]. Ciba-Geigy
(now Novartis) introduced DFO B to the market as a strong metal
chelator and this compound was later approved by US Food and
Drug Administration (FDA) in 1968 as “Desferal” for the treatment
of iron poisoning (iron overloading) [22].
Albomycins are hydroxamate sideromycins. They were reported
previously as grisein [23] and were first isolated in 1947, but their
structures were not fully characterized till 1982 [24] (see section
2.4.1.1).
Many other hydroxamate siderophores have since been isolated
and reported [25]. In the last two decades (2000-to date), more
than 135 new members have been added to the family (entries
10e61, Table 1), many extracted mainly from bacterial species
collected from the Atlantic Ocean [26]. Most hydroxamate side-
rophores are hydrophilic. In contrast, most marine siderophores are
amphiphilic, having both hydrophilic and hydrophobic parts in
their structure, the latter enabling the siderophore to formmicelles
when complexed to Fe(III), thereby increasing the availability of the
complex to the cell in the seawater environment [27]. Ferrioxamine
E and G are among the most soluble marine siderophores [26].
Table 1 shows most of the hydroxamate siderophores isolated in
the period 2000e2020, their structures and the species that pro-
duce them.
From a structural point of view, all the siderophores in Table 1
contain the hydroxamate chelating unit, either alone as in entries
10e29 and 34e38, or mixed with other binding units as in entries
30e33 and 39e61. The hydroxamate parts are derived from Orn,
Lys, or N-hydroxydiaminoalkane [17]. In Orn-derived hydrox-
amates, the d-N of the Orn is hydroxylated and acylated. The
acylation moieties vary between formyl, as in 13, 17, 23e26, 30, 31,
and 33, acetyl as in 10e12 and 14e15, malonyl as in 16, or anhydro-
mevalonyl as in 20e22 and 28, 3-hydroxy-butanoyl as in 27, 3-
methyl-glutaconyl as in 29 (this acyl is an intermediate in leucine
metabolism [84]), fatty acid as in 56e57, a-COOH of the Orn itself
forming a six membered cycle as in 23e26, or the a-COOH of
another amino acid within the backbone (Arg, Asn, or Ser) as in
17e19 and 24e26. Some siderophores show two or more different
Fig. 1. Representative natural siderophores with different binding units (hydroxamic groups are shown in purple, catechol in blue, a-hydroxy carboxylic acid in green, and other
groups in maroon). (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)
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same molecule as in 17e19 and 23e26.
Also, ε-hydroxamate Lys residues are found in amamistatins
(30), brasilibactin (31), nocardimicins (32 and 33), with the acyl-
ating moieties varying as in the Orn siderophores.
Other hydroxamate siderophores are derived from N-hydroxy-
1,5-diaminopentane as in 34e38 and are usually acylated with a
succinic moiety. N-hydroxy-1,5-diaminobutane is found in 38.
Many of these hydroxamate siderophores are peptides. They
show a variety of structures. In agreement with the previously
known representative siderophores, siderophores 10e13 are linear
with hydroxamate appendages, as in albomycin (3) (although 11
has a cyclic part but the chelating unit is linear). Siderophores
14e16 are cyclic peptides (lactams) with exocyclic hydroxamate
appendages as in ferrichrome 1.
Entries 17e22 resemble coprogen (5), a tris hydroxamate side-
rophore with a cyclic di-Orn part with hydroxamate side chains.
The denticity is extended to hexadentate through the acyl (pep-
tidyl) part of the hydroxamate moieties to include an additional
functionalized Orn as in 17e19, or other hydroxamate containing
acyl as in 20e22.
The hydroxamate in the non-peptidyl siderophores are found
only with the backbone (not as appendages) and the backbones are
either linear as in 35e37 or cyclic (endo cyclic hydroxamate) as in
38e39.102.2. Chemical synthesis of hydroxamate residues in siderophores
Several synthetic pathways can be used to prepare hydroxamic
acids. In this regard, these acids can be synthesized from carboxylic
acids [85], esters [86], aldehydes [87], alkyl halides [86], amines
[88,89], and nitro compounds [90,91]. All reported methods can be
briefly outlined as one of the five possible routes (either full or sub-
route) shown in Scheme 1, which illustrates the most general ap-
proaches for the synthesis of hydroxamic acids from alkyl amines,
hydroxyl amine or simple amides.2.2.1. Synthesis of d-acyl-d-N-Hydroxy-Orn building block
To prepare the d-acyl-d-N-hydroxy-ornithine building unit,
most of the reported procedures involved the conversion of the
alkylamine (in this case the Orn side chain) to N-hydroxyl alkyl-
amine and then to N-acyl-N-hydroxyl alkylamine (the red route in
Scheme 1). The hydroxylation of the primary amine (d-NH2) is the
crucial step in the synthesis, and various approaches for this reac-
tion have been reported in the literature. The syntheses start with
Orn, with suitable protecting groups for the a-NH2 and COOH. Next,
d-N is hydroxylated mostly with benzoyl peroxide in a biphasic
mixture at pH ¼ 10.5 [88,89,92] (Scheme 2). Although this is the
most widely used protocol, it is hampered by low yield and requires
critical purification due to the formation of the d-benzamide by-
product. Another peroxide, dimethyl dioxirane (DMD) with
Fig. 2. Representative hydroxamate-derived siderophores.
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Table 1
Hydroxamate siderophores isolated and reported in 2000e2020.
# Siderophore Structure Secreted by Ref
Ornithine-derived siderophores
10 Amphibactins B-I, S, and T Amphibactin B-I:
Proteobacteriu, Vibrio sp. R-10
Amphibactin S and T:
Vibrio sp. HC0601C5
[28,29]
11 Marinobactins A, B, C, D1, D2, E,
and F
Marinobacter sp. strains DS40M6 and DS40M8 [30,31]
12 Moanachelins Marine bacterial isolate Vibrio sp. Nt1 [32]
13 Coelichelin Nocardia tenerifensis NBRC 101015 [33]
(continued on next page)
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Table 1 (continued )
# Siderophore Structure Secreted by Ref
14 AS2524371, and AS2488059 Acremonium persicinum MF-347833 [34]




17 Peucechelin Streptomyces. peucetius [37]
18 Thermochelin Thermocrispum agreste DSM 44070 [38]
19 Erythrochelin Strain S. erythraea [39]
D. Al Shaer et al. / European Journal of Medicinal Chemistry 208 (2020) 1127916
13
Table 1 (continued )
# Siderophore Structure Secreted by Ref
20 Metachelins 1, 2, and 3 Metarhizium robertsii [40]
21 Beauverichelin A Beauveria bassiana [41]
22 Talarazines AE Fungus, Talaromyces sp. (CMB-W045) [42]
23 Albisporachelin Amycolatopsis [43]
24 Tsukubachelin Streptomyces sp. TM-74 [44]
(continued on next page)
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Table 1 (continued )
# Siderophore Structure Secreted by Ref
25 Albachelin Amycolatopsis alba [45]
26 Scabichelin and Turgichelin Scabichelin: Streptomyces antibioticus NBRC 13838/Streptomyces
scabies JCM 7914
Turgichelin:
Streptomyces turgidiscabies JCM 10429
[46]
27 Vicibactin Rhizobium leguminosarum ATCC 14479 bv. Trifolii [47]
28 Fusigen Aureobasidium pullulans HN6.2 [48]
29 Basidiochrome Mycorrhizal fungi Ceratobasidium and Rhizoctonia spp. [49]
Lysine-derived hydroxamate siderophores
30 Amamistatins A, and B Actinomycete Nocardia asteroides SCRC-A2359 [50,51]
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Table 1 (continued )
# Siderophore Structure Secreted by Ref
31 Brasilibactin A Actinomycete Nocardia brasiliensis IFM 0995 [52]
32 Nocardimicins A-F Nocardia sp. TP-A0674 [53]
33 Nocardimicins G-I Nocardia nova JCM 6044 [54]
N-Hydroxy-diaminoalkane-derived hydroxamate siderophores
34 Nocardichelins A and, B Nocardia Strain Acta 3026 [55]
35 Tenacibactins A, and B Marine-derived bacterium Tenacibaculum sp. A4K-17 [56]
(continued on next page)
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Table 1 (continued )
# Siderophore Structure Secreted by Ref
36 Legonoxamine A1, and B2 The soil bacterium, Streptomyces sp. MA37 [57]
37 Bisucaberin Salmonicida [58]
38 Avaroferrin Shewanella algae B516 [59]
Mixed
39 Rhodochelin Rhodococcus jostii RHA1 [60]
40 Lystabactins A, B, and C Marine
Pseudoalteromonas sp
[61]
D. Al Shaer et al. / European Journal of Medicinal Chemistry 208 (2020) 11279110
17
Table 1 (continued )
# Siderophore Structure Secreted by Ref
41 Rhodobactin Rhodococcus erythropolis PR4 [62]
42 Heterobactins A, S1, and S2 Rhodococcus erythropolis PR4 [63]
43 JBIR-16 Nocardia tenerifensis NBRC 101015 [64]
44 Fuscachelins A-C Thermobifida fusca [65]
45 Anguibactin Vibrio sp. DS40M4 [66]
46 Fimsbactins A-C Acinetobacter baumannii and Acinetobacter baylyi [67]
(continued on next page)
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Table 1 (continued )
# Siderophore Structure Secreted by Ref
47 Aquachelins A, B, C, D, I, and J For A-D:
Halomonas aquamarina strain DS40M3
For I, J:
Halomonas meridiana str. HC4321C1
[30]
48 Variochelins A, and B Variovorax boronicumulans [68]
49 Imaqobactin Arctic Marine Bacterium Variovorax Species RKJM285 [69]
50 Variobactins A, and B Variovorax paradoxus P4B [70]
51 Vacidobactins A, and B Variovorax [70]
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Table 1 (continued )
# Siderophore Structure Secreted by Ref
52 Loihichelins A-F Marine bacterium Halomonas sp. LOB-5 [71]
53 Pacifibactin Alcanivorax pacificus [72]
54 Serobactins (A-C) Grass endophyte Herbaspirillum seropedicae [73]
55 Cupriachelin Bioplastic Producer Cupriavidus necator H16 [74]
56 Woodybactins A-D A marine Shewanella [75]
57 Ochrobactins A, B, and C Coastal a-proteobacterium Ochrobactrum sp. SP18 [76]
(continued on next page)
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Table 1 (continued )
# Siderophore Structure Secreted by Ref
58 Synechobactins A, B, and C Coastal marine cyanobacterium Synechococcus sp. PCC 7002 [77]
59 Schizokinen, and Schizokinen A Rhizobium leguminosarum IARI 917 [78]
60 Baumannoferrins A and B Acinetobacter baumannii [79]
61 Catenulobactins B Catenuloplanes sp. RD067331 [80]
Other Interesting
62 Mirubactin Actinosynnema mirum [81]
63 Gramibactin Rhizosphere bacteria (Paraburkholderia graminis) [82]
64 Strepturidin Streptomyces albus DSM 40763 [83]
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nitrone (the N-oxide of the imine) and then the hydroxamic acid in
two steps [87] (Scheme 3). In other cases, and following the same
imine-nitrone approach, the hydroxylation step was done by
reacting the d-N of Orn with benzaldehyde in basic medium, fol-
lowed by the addition of an oxidizing agent (m-CPBA) and then a
treatment with acid to obtain N-OH. The advantage of this func-
tionalization is that it can be done either to the building block
(Scheme 3) or to the Orn residue side chains after the peptide has
been built [87].
Once the d-NH2 has been hydroxylated, the acylation step is
carried out using strong amide formation strategies, such as acyl
halides [89,92], acyl anhydrides [87] and HATU [88], due to lower
nucleophilicity of the hydroxylated amine compared to the free
amine.
Other syntheses reported the preparation of the hydroxamate
Orn starting from different amino acids. A full synthesis of ferri-
chrome in 1969 described the conversion of d-nitro norvaline (non-
branched Val) into d-N-hydroxy ornithine by reducing the nitro
groupwith zinc in an aqueous ammonium chloride solution [90,91]
(Scheme 4). Another protocol included the conversion of the COOH
side chain of glutamic acid to OH then its attachment to a protected
simple hydroxamic acid (blue route in Scheme 1) using diisopropyl
azodicarboxylate and triphenyl phosphine [85] (Scheme 4).
2.2.2. Synthesis of N-5-aminopentyl-N(hydroxy)-succinic acid
building block
Reported syntheses of N-5-aminopentyl-N(hydroxy)-succi-
namic acid building unit started with the protected hydroxylamine,
followed by an alkylation step with a cyano aldehyde (4-
cyanobutanal) as in the preparation of desferrioxamine B [93], or
a haloalkane nitrile (5-chloro valeronitrile) as in the synthesis of
bisucaberin [94] (see Scheme 5). The prepared cyanoalkylhydrox-
ylamine is divided into two parts, the nitrile group in one of them is
reduced to an amine group and acylation is done using succinic
anhydride (the route followed is shown by green dashed lines,
Scheme 1). The same route was reported for the synthesis of alca-
ligin but with a shorter alkyl part to prepare the N-5-aminobutyl-
N(hydroxy)-succinic acid [95].
2.2.3. Synthesis of other hydroxamate building blocks
In some artificial siderophores, the hydroxamate moiety was
embedded in the backbone through a-N-hydroxy amino acids
prepared indirectly from other closely related acids. For example, a-
benzyloxyglycine was obtained by reacting bromoacetic acid tert-
butyl ester and O-benzylhydroxylamine [96]. N-benzyloxyalanine
(or N-benzyloxyphenylalanine) was prepared starting from D-lactic
acid (or D-phenyllactic) acid t-butyl ester by converting the a-OH toScheme 1. Possible routes for the preparation of hydroxamic acid from different starting
arrows (black and coloured represent reported routes for hydroxamic acid preparation in g
22a triflate intermediate, followed by the reaction with O-benzylhy-
droxylamine [97]. The SN2 attack of the benzolyxyamine resulted
with inverted configuration of a-carbon. The amide bond was then
formed by condensing the hydroxylated a-N with an a-COOH of
another amino acid using an effective form of activated acid [96,98].
All these methods followed the green route of Scheme 1 by intro-
ducing the alkyl part into a previously prepared benzyl protected-
hydroxyl amine (Scheme 6).
A more recent study hydroxylated the a-N of the amino acid
with m-CPBA after alkylating it with bromoacetonitrile (converting
it temporarily into a secondary amine prior to hydroxylation,
making the latter much more efficient) [99] (Scheme 6).
2.2.4. Incorporating the hydroxamate building block into the
backbone
In literature, the synthesized hydroxamate building blocks were
incorporated into the siderophore molecule through various stra-
tegies. Somewere done on solid phase, the others in solution phase
(see Table 2).
2.3. Binding affinity towards iron
Siderophores, in general, form strong complexes with Fe (III),
with thermodynamic formation constants ß up to 1049 for the tris-
catecholate enterobactin (Fig. 1), compared to 1025 for EDTA, a
widely used complexing agent for metal ions. Tris hydroxamate
siderophores also show high formation constants of ~1030. In the
fully deprotonated forms of ligands (at highly basic conditions),
catecholate siderophores show greater binding to Fe(III) than
hydroxamates (the difference in log ß values can go up to 19 units,
which means that the concentration of the catecholate-Fe complex
is 1019 times that of hydroxamate-Fe under same conditions).
However, at physiological pH (pH ¼ 7.4), the binding affinity (re-
flected by pFe3þ, which equals -log[Fe3þ]free at pH ¼ 7.4, [Fe3þ]
total ¼ 106 M and [Ligand]total ¼ 105 M) of the two siderophores
is comparable (the difference in binding affinities is much lower).
This observation is attributed to the acidic character of the
hydroxamates, a feature that increases the proportion of deproto-
natedmolecules (ready to bind to Fe(III)) of hydroxamate compared
to catecholate.
For comparative purposes, Table 3 shows the formation con-
stants and iron affinity for several siderophores with different
chelating groups.
2.4. Applications of hydroxamate molecules and hydroxamate
siderophores
Hydroxamic acids have found many applications in medical andcompounds (coloured arrows represent routes reported for siderophore synthesis, all
eneral).
Scheme 2. Synthesis of ‘PG1-Orn(acyl,OBz)-OPG2’ building block, using bezoyl peroxide (for the hydroxylation step). (R ¼ H, X ¼ EDC active ester) in pyoverdin D. [88], (R ¼ CH3,
X ¼ Cl) in amphibactin-T [92] and albomycin [89].
Scheme 3. Synthesis of ‘PG1-Orn(acyl,OBz)-OPG2’ building block through the imine-nitrone intermediates and using DMD or PhCHO [87].
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can be therapeutic or diagnostic [110]. The presence of hydroxy
substituents on the amide bonds of an active peptide enhances its
stability against enzymatic degradation [96]. Furthermore,
hydroxamic acids inhibit methionine aminopeptidase (MetAP), an
essential enzyme in protein synthesis in a variety of organisms. This
inhibition enables the use of hydroxamic acids as potent antibac-
terial or antitumor agents [96,111]. Also, these acids have the po-
tential to inhibit metalloproteases and HIV protease, and they show
activity in immune suppression [96].
As metal chelators, Desferal, the brand name of desferrioxamine
B (6), was the first drug used for the treatment of metal poisoning,
namely iron overloading [22,112]. Also, the hydroxamate groups
have shown unprecedented activity against the growth of
P. aeruginosa biofilms (which confer cells extra resistance to anti-
biotics by adhering in the form of a film) when theywere combined
with glycol motifs in a bifunctional molecule, in which the glycol
targeted the adhesion of cells and hydroxamate deprived cells of
iron [113].
In this review, we focus on and discuss the use of hydroxamate
siderophores as Trojan horses to overcome bacterial resistance to
antibiotics.2.4.1. HA siderophores-antibiotic conjugates (application as Trojan
horses)
After being excreted and complexed to Fe(III), the loaded side-
rophores are recognized by specific protein receptors present on23the microbial cell membrane. They are then transferred through
specified cycles to their target inside the cell (cytoplasm or some-
times periplasm in some gram-negative bacteria). Fe(III) is then
released form the siderophore through certain mechanisms [11,12],
reduced to Fe(II) and metabolized [8].
The microorganisms that produce hydroxamate siderophores
have a special protein receptor, FhuA, embedded in their mem-
branes to recognize andmediate the uptake of the iron-siderophore
complex [11,16,114]. FhuA may also be present in the membrane of
other microorganisms that do not produce endogenous hydrox-
amate siderophores yet can take up the hydroxamate siderophores
produced by other organisms [13].
Some studies have suggested that the protein receptors recog-
nize and identify key points in the siderophore backbone. Others
propose that recognition occurs via identification of the steric
configuration of the e-donating atoms around the central iron in
the inner coordination sphere [13,17]. The latter notionmay explain
how some species can take up iron from xenosiderophore com-
plexes. A study by Shanzer’s group suggested that the recognition
takes place in two domains: first, the configuration of the complex
around iron; and second, the spatial orientation of the functional
groups (C¼O) with respect to the inner coordination sphere
[115,116]. It is likely that microorganisms have two types of
receptorsdspecific ones to identify endogenous siderophore-iron
complexes and more general ones that identify the core of the
xenosiderophore-iron complexes.
Some bacterial strains exploit the greed for theft of other species
Scheme 4. Synthesis of ‘PG1-Orn(acyl,OBn)-OPG2’ starting from 3 different amino acids.
Scheme 5. Synthesis of N-5-aminopentyl-N(hydroxy)-succinic acid building block in desferrioxamine B [93] and bisucaberin [94].
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biocidal moiety. The resulting conjugate is called a “sideromycin”.
These molecules are then released into the matrix as Trojan horses
to poison competing opponent cells.
2.4.1.1. Natural conjugates (sideromycins). Natural sideromycins are
highly specific against certain types of bacteria and are taken up
through the same pathway as the corresponding type of side-
rophores with respect to the binding unit.
The first reported sideromycin was grisein, discovered by
Waksman’s group in 1947 [23]. It was isolated from a strain of
Streptomyces griseus. It showed antimicrobial activity against many
strains of bacteria but its structurewas not elucidated then andwas
partially characterized in 1951 [117]. Grisein was later reported as
albomycin (3) [112]. Albomycins are the most widely known nat-
ural sideromycins. In 1951, Gause and Brazhnikova isolated an
albomycin from Actinomyces suibtropicus, a species of streptomy-
cetes [118]. It was found to strongly inhibit the growth of some
gram-positive bacteria, such as S. aureus, S. pneumoniae and24B. subtilis, as well as some gram-negative bacteria [112]. The activity
of this albomycin was found to be ten times stronger than that of
penicillin [118], and it was used in the Soviet Union as an antibiotic.
Its structure was firmly established by Benz and coworkers in 1982
[24]. Similarities between grisein and albomycin that led to
conclude that they are the same compound have been discussed in
the literature [119]. Other examples of hydroxamate sideromycins
are salmycins and ferrimycins (Table 4).
All bacteria susceptible to the microbicidal activity of these
hydroxamate sideromycins were found to have the FhuA receptor
in their membranes. These sideromycins function better under iron
starvation conditions than under conditions of sufficiency [3]. Iron
starvation can be achieved by using biostatic agents (strong che-
lators that bind iron tightly).
In addition to these sideromycins, another seryl tRNA synthe-
tase inhibitor, SB-217452 [122], was isolated from a Streptomyces
species. Although structural characterization showed that SB-
217452 contains the same nucleoside moiety present in albomy-
cin, it showed very weak antibacterial activity compared to the
Scheme 6. Reported syntheses of a-N-benzyloxy amino acids through two routes: a) alkylation of hydroxylamine [97] and b) hydroxylation of alkylamine [99].
Table 2








Pyoverdin Fig. 1 Fmoc/tBu Super acid-labile Rink acid resin
(solid phase)
[88]
Amphibactin-T 10 Fmoc/tBu CTC-polystyrene resin (solid phase) [92]
Albomycin 3 Fmoc/tBu Solution phase [89]
Ferrichrome 1 Boc/Bzl Solution phase [90]
DIG-siderophore
(conj.)





Desferrioxamine 6 Metal-templated Cyclic Trimerization Solution phase [100]
Bisucaberin 37 Boc/Bzl Solution phase [101]
Alcaligin 7 Diphenylphosphoryl azide (DPPA) þ triethyl amine Solution phase [95]
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contain the chelator moiety that mediates the uptake of albomycin
[13,122]. This example and many others clearly demonstrate the
role played by the chelator moiety in overcoming the low perme-
ability of the pathogenic cell wall towards the bactericidal moiety
alone.
Albomycin (3) consists of a linear Orn-derived tri hydroxamate.
The tri peptide is linked through its C-terminus to a glycoside entity
by a di-seryl linker. When the competing bacteria internalize the
conjugate-iron complex, peptidases release the warhead, thus
inducing bacterial death [13] (Fig. 3-A). Ferrimycin (66) resembles
the ferrioxamine family in its chelating unit, which is a linear non-25peptidyl tris-hydroxamate derived from alternative N-hydroxy-
diaminopentane and succinic acid with a 4-amino-5-
hydroxybenzamide linkage to an iminoester-substituted lactam
antibiotic [112]. Salmycin consists of danoxamine siderophore (9)
attached to an aminoglycoside through a succinic linker [121].
When the hydroxamate moieties are engaged with iron complex-
ation, the payload remains attached to the conjugate. Once the
reductase of the cell frees the iron, the protonated hydroxamate
attacks the ester group causing a cyclization reaction that results in
the release of the antibiotic. This only happens after the competing
cell obtains the iron from the stolen complex [13,123]. The mech-
anism of drug release is shown in Fig. 3-B [123].
Table 3
Comparison of the thermodynamic constants for various representative tris-hydroxamate siderophores and their Fe(III) complexes with that of enterobactin.
Siderophores Entry no. pKa Logß110 apFe3þ Ref
Enterobactin (triscatecholate) Fig. 1 6.00 49 34.3 [102,103]
7.50
8.55
Ferrichrome 1 8.11 29.07 25.2 [104,105]
9.00
9.83
Ferricrocin 2 8.14 30.4 26.5 [106]
9.01
9.92
Ferrioxamine B 6 8.39 30.6 26.6 [104e106]
9.03
9.70
Basidiochrome 30 Not evaluated 27.8 25 [107]
Aquachelin-C (bi-hydroxamate) 40 3.79 (COOH) 31.4 e [108]
8.73 (CONOH)
9.52 (CONOH)
Marinobactin-D (bi-hydroxamate) 11 3.75 (COOH) Not evaluated e [108]
8.47 (CONOH)
9.40 (CONOH)
Marinobactin-E (bi-hydroxamate) 11 3.85 (COOH) 31.8 e [108]
8.89 (CONOH)
9.52 (CONOH)
a pFe3þ ¼ -log[Fe3þ]free at pH ¼ 7.4, [Fe3þ]total ¼ 106 M, [Ligand]total ¼ 105 M.
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affected by the conjugate because it does not have a target for the
warhead or the related enzyme that causes drug release [13]. Also,
vulnerable bacteria can readily develop resistance against these
sideromycins through the deletion of the hydroxamate membrane
receptor [14].2.4.1.2. Artificial conjugates mimicking the natural ones. The activity
of the natural sideromycins opened the door for research into new
conjugates. In this regard, attention was turned to tuning the
structure of the chelators and varying the antimicrobial moiety,
thereby providing promising tools for tackling fatal multidrug-
resistant bacteria.
The first synthetic conjugate 85was reported by Zahner in 1977
[13]. He hybridized DFO B with a sulfonamide directly through an
amide bond (no linker) between the available primary amine of the
chelatormoiety and the carboxyl of the sulfonamide. Many artificial
hybrids containing hydroxamate chelators have been reported to
date (Table 5), with cargos varying between cephalosporines,
flouroquinolines and others. However, none of the hydroxamate-
drug hybrids have yet been approved as a drug. Cefiderocol (S-
649266) is the first and only siderophore-drug conjugate to be
authorized by the FDA (November 2019) [124]. This drug consists of
a catechol chelating unit and a cephalosporin antibiotic cargo [125]
(see section 3).
In summary, conjugates 68e73 are semi synthetic sideromycins
that share the same chelator moiety as albomycin (3) which is a
linear Orn-derived tri hydroxamate. The antibiotic moieties in
these conjugates varies between ß-lactams as in 68 and 69, and
fluoroquinolones as in 70, attached to the C-terminal of the
chelating peptide backbone. In conjugates 71e73, the antibiotics
digoxigenin, biotin and virgimycin, respectively, are attached to the
tripeptide backbone via different linkers through its N-terminals.
Conjugates 74e77 are totally synthetic; the chelatormoiety is an
iso cyanuric acid-based tri Orn hydroxamate, inspired by the nat-
ural bi hydroxamate siderophore rhodotorulic (4). The antibiotic is
directly attached to the acyl part of the hydroxamate, enabling the
preparation of multi-warhead conjugates [142].26Conjugates 78e82 were synthesized to illustrate the effect of
linker on overall activity. All are containing the same chelator
moiety, desferrioxamine B, and ciprofloxacin antibiotic. The linkers
vary from stable uncleavable succinic moiety 78 to esterase-
cleavable 79, phosphatase-cleavable 80 and reductase-cleavable
81, ending with thiol-maleimide linker 82. The mechanisms of
drug release are shown in Fig. 4 [132]. Conjugates 82e84 share the
same desferrioxamine B chelator, the same linker (thiol maleimide)
and three different antibiotics.
Conjugates 86e88 contain danoxamine analogue chelators with
differing denticity (mono, bi and tri hydroxamate) and three
different antibiotics attached through a stable linker.
Conjugates 89e102 contain mixed chelators. Compounds
89e98 are biscatecholate-mono hydroxamate, with various anti-
biotic warheads, while 99e102 are pyoverdine-derived (bis
hydroxamate, mono catecholate) chelators attached to a range of
drugs through different linkers at distinct positions of the pyo-
verdine scaffold.
Conjugate 106 is mycobactin chelator (employing lysine residue
as the hydroxamate-bearing moiety) attached to the antibiotic
artemisinin.
2.4.1.2.1. Summary of the antibacterial activity of these conju-
gates. Most of these conjugates had moderate to low antibacterial
activity. Conjugates with ß-lactams showed better performance
than those with non ß-lactams [14]. The activity of the conjugates
under iron-deficient conditions was enhanced but was lower than
that of the parent antibiotic alone in most cases. This observation
may be attributable to premature release, non-suitable substrates
for enzymatic cleavage, or readily developed resistance [135]. The
modification of linkers (trimethyl lock) in 79e80 did not achieve
better results.
Here are some examples with the main conclusions learned
from their study:
Conjugates 86e88 showed that the denticity of the chelator is
crucial, where it should form a 1:1 complex with Fe(III) to actively
transport the conjugate [134,135].
Conjugate 92 employs a bis catecholate-mono hydroxamate
chelator that is analogous to fimsbactin (a siderophore produced by
Table 4
Natural hydroxamate sideromycins, chelator moieties are shown in black and purple, linkers in green and antibiotic moiety in red.
# Sideromycin Structure Produced naturally by Year/ref.
General structure
65 Grisein Structure not fully elucidated Streptomyces griseus 1947 [23,120]
3 Albomycin Actinomyces suibtropicus 1951 [118]
66 Ferrimycin 1960 [112]
67 Salmycin Streptomyces violaceus 1995 [121]
Fig. 3. Possible mechanisms for drug release from sideromycin: a) albomycin and b) salmycin.
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Table 5
Artificial hydroxamate siderophore-drug (SD) conjugates, chelator moieties are shown in black and purple, linkers in green and antibiotic moiety in red.
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Table 5 (continued )






79 Esterase release [132]
80 Phosphatase release [132]
81 Reductase cleave [112]
82 [133]
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Table 5 (continued )
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Table 5 (continued )
# Structure Antibiotic ref.
97 Cephem [13,14]
98 Vancomycin [13]
99 Norofloxacin cleavable [112]
100 Norofloxacin non cleavable [112]
101 Ampicillin [112,140]
102 [141]
(continued on next page)
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# Structure Antibiotic ref.
103 Artemisinin [13]
Fig. 4. “Trimethyl lock” mechanism of drug release in conjugates: a) 79 b)80 [132] and c) 81 [13].
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high activity against A. baumannii, again demonstrating the
vulnerability of a bacterium against a hybrid of its own siderophore
(advantage of endogenous over xenogenous siderophores).
Furthermore, 92 mediates uptake through two receptors in E. coli,
namely Cir (for the catechol) and FhuA (for the hydroxamate)
[14,112].
The same mixed bis-catecholate mono-hydroxamate chelator
hybridized with a ciprofloxacin warhead as in 95, shows no activity
against A. baumannii [112,134], emphasizing the importance of
harmony between the uptake cycle of the chelator and the target of
the antibiotic. The cycle of this conjugate ends in the periplasm,
while the target of ciprofloxacin (unlike the loracarbef in 92) is the
cytoplasm, thereby explaining the lack of activity of 95.
A strong promising example is conjugate 96, which conferred
the gram-positive antibiotic daptomycin activity against some
gram-negative bacteria [138,139]. This conjugate revealed that that
large molecules (such as daptomycin >500 Dawhich cannot diffuse33into the cell like the smaller molecules) can also be transported into
the cell through specific iron-mediated receptors [112].
Conjugate 103 was highly specific to M. tuberculosis. The
chelating moiety in conjugate 103 resembles mycobactin, the
siderophore produced by M. tuberculosis. However, 103 did not
attack other gram-positive or -negative bacteria [13,112]. Again, this
observation indicates that the use of the pathogen’s own side-
rophore may be useful. The same conclusion was drawn from
pyoverdine-derived conjugate 101 against the pyoverdine producer
P. aeruginosa [140].
2.4.1.3. Rational design for choice of artificial siderophore-drug con-
jugates. Traditional antibiotics are classified into four groups on the
basis of their cellular targets. The targets are cell wall assembly (as
for ß-lactams and glycopeptides), protein synthesis (as for amino-
glycosides and macrolides), DNA/RNA replication (as for flour-
oquinolines and sulfonamides) and membrane disruption (as for
lipodepsipeptides; daptomycin) [112]. Small antibiotics (<500 Da)
Fig. 5. Hydroxamate chelator-antibody conjugates for imaging applications.
Fig. 6. Chemical structure of Cefiderocol.
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of gram-negative bacteria and they are usually broad spectrum. On
the other hand, glycopeptides and daptomycin are active only
against gram-positive bacteria, with targets present on the outer
part of the cell [112]. Hybridizing these antibiotics with side-
rophores can broaden or narrow the spectrum of activity of the
antibiotic warhead.
2.4.1.3.1. Choosing the chelator. The chelator of choice depends
on the pathogen targeted, its outer membrane protein receptors
(what types of siderophores it can recognize), and the iron cycle
(where Fe(III) is releaseddin the cytoplasm or periplasm) [135]. For
example, trihydroxamate is suitable to drive cytoplasmic drugs
while biscatechocalate-hydroxamate is suitable for periplasmic
drugs for gram-negative bacteria.
2.4.1.3.2. Role played by the linker. Linkers play a critical role in
determining the efficiency of the conjugate. Premature release of
thewarhead or halting it back from attacking the targetmay fail the34whole process. The choice of linker depends on the above-
mentioned factors. Several types have been reported, some of
which have been mentioned before. Another kind of chelator is
ß-lactam as a linker attached to any type of antibiotic. The release
mechanism depends on the attack of ß-lactamase to free the other
antibiotic payload [13].
2.4.1.3.3. Choosing the antibiotic. The antibiotic warhead target
determines where the release takes place, and, consequently, the
type of linker to be used. Evenwhen taking all factors carefully into
consideration, the bacterial fast development of resistance remains
the biggest challenge.
2.4.2. Other hydroxamate siderophore conjugates
In all the previous conjugates mentioned, the chelating units are
the moiety that drives them towards the target and the payloads
are the antibiotics. Hydroxamate chelators can also be used in other
conjugates in which an antibody is the driving moiety and a radi-
olabelled metal-chelator complex is the cargo used for imaging
[113,143] (Fig. 5).
3. Cefiderocol (FETROJA®): the first siderophore-drug
conjugate in the market
Cefiderocol (previously known S-649266) is a novel catechol-
based siderophore that targets gram-negative bacteria, including
strains with carbapenem resistance, via a Trojan horse active
transport mechanism [125,144]. The aminoacyl catechol moiety is
attached with a di-methylene linker to the pyrrolidine ring of the
antibiotic [144,145] (Fig. 6).
The structure of the payload in cefiderocol combines the fea-
tures of the antibiotics ceftazidime and cefepime, thereby boosting
D. Al Shaer et al. / European Journal of Medicinal Chemistry 208 (2020) 11279128activity against gram-negative bacteria, as well as stability. The
quaternized N-methyl-pyrrolidine and the carboxylate moieties of
cefiderocol form a zwitterion that enhances water solubility,
degradation resistance, and capacity to rapidly penetrate the outer
cell membrane of gram-negative bacteria [146]. GR69153 (cefete-
col), M  14659 and S-9096 are other catechol-cephalosporine
conjugates that showed strong antibacterial activity in vitro, but
were not successful in vivo [145].
Cefiderocol was approved by the FDA on November 14, 2019
[124]. It is used for the treatment of complicated urinary tract in-
fections (cUTI), including pyelonephritis caused by susceptible
gram-negative microorganisms. It is administered intravenously. It
has some reported adverse effects, including diarrhea, infusion site
reactions, constipation, rash, candidiasis, cough, elevations in liver
tests, headache, hypokalemia, nausea, and vomiting [147].
4. Conclusion
Forty years of research have been devoted to the synthesis and
use of sideromycins to tackle pathogens. Among these conjugates,
only one has reached the market, namely Cefiderocol, which was
approved by the FDA in 2019. Although Cefiderocol contains a
catechol (not a hydroxamic) binding unitdthe field remains open
for the development of others. No other reported artificial conju-
gates have been commercialized to date, but they have all
contributed to bringing the pieces of the puzzle together. Inspired
by albomycins, ferrimycins and salmycins, hydroxamate-based
siderophores are well positioned to achieve success. While the
full picture of successful conjugate design and development is
gaining clarity, more research efforts are required to optimize the
technology.
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Bzl protecting groupa b s t r a c t
Herein a friendly method for the preparation of 1-hydroxypyridine-2-one (1,2-HOPO)-containing pep-
tides is described. The elongation of the peptide is carried out on a solid support, using a protecting group
for the e-amino of the Lys that is removable in very mild conditions and that does not provoke cleavage of
the peptide from the resin. Once the e-amino of the Lys is released, HOPO can be incorporated using a
commercially available derivative (1,2-HOPO-4-COOH), which has a carboxylic acid at position 4 of the
aromatic ring. 1,2-HOPO-4-COOH can be introduced with the free N-hydroxyl or protected with the ben-
zyl group. The former is recommended in many cases. If the protected derivative is to be used, the benzyl
group can be removed during global deprotection and cleavage from the resin by adding trifluo-
romethanesulfonic acid to the cleavage cocktail.
 2020 Elsevier Ltd. All rights reserved.Introduction
Metals play pivotal roles in living organisms and their imbal-
ance can cause disorders in the form of diseases.[1,2] However,
metal sequestration can enhance therapy and diagnostics. In this
regard, chelators are key moieties in many medicinal chemistry
programs.[3] Siderophores (iron carriers in Greek) are an impor-
tant class of natural chelators.[4] As their name indicates, sidero-
phores are secreted by microorganisms to acquire nutrient Fe(III)
from the surroundings under conditions of iron starvation. In nat-
ure, a large number of bidentate molecules can complex Fe(III), and
a combination of three of these molecules are present in most nat-
ural siderophores. The most common bidentate moieties are cate-
chols, a-hydroxy carboxylic derivatives, and hydroxamic acids.
Thus, in some natural peptide siderophores, the hydroxamic acid
structure is present into the Nd-acetyl, Nd-hydroxy ornithine resi-dues. However, little attention has been paid to 1-hydrox-
ypyridin-2-one (1) (1,2-HOPO) derivatives, which have found
application as additives in carbodiimide-mediated peptide bond
formation.[5] These 1,2-HOPO moieties are isoelectronic to both
the ones found into the hydroxamic peptide siderophores and
the catechols.[6–7] Furthermore, two commercially available car-
boxylic acid derivatives of 1,2-HOPO, in position 4 and 6 [4/6-car-
boxy-1-hydroxypyridin-2-one (1,2-HOPO-4-COOH (2) /1,2-HOPO-
6-COOH (3))] (Fig. 1), can facilitate its incorporation into an organic
scaffold or other biological molecule of interest.
The literature provides only a few examples, mainly by Ray-
mond [6,8–9], and Tetard[7,10] groups, in which the 1,2-HOPO-
6-COOH (3) has been introduced into triamine-based cores in solu-
tion. In all, the N-hydroxyl of the 1,2-HOPO was masked with a
benzyl group (Bzl) prior to the incorporation. Herein, and due to
the importance of having chelator moieties to be incorporated onto
different biological interesting structures such as peptides, a
friendly strategy for the preparation of 1,2-HOPO-4-COOH-con-
taining peptides is described. The method is based on the use of
the conveniently Solid-Phase Peptide Synthesis strategy, paying
special attention to the need of using a protecting group for the
N-OH of the HOPO moiety. Thus, comparison of masked and un-
masked N-OH was investigated. The presence of peptides in the
chelator can be important for modulating the solubility of these
Fig. 1. Structures of 1,2-HOPO derivatives.
2 D. Al Shaer et al. / Tetrahedron Letters 61 (2020) 152299compounds, and, possibly, their selectivity and affinity in front of
the metals, as well.Results and discussion
The first strategy consists of building a Lys-containing peptide
in solid-phase using a Rink-amide resin. The methyltrityl (Mtt)
group is used to protect the e-amino of the Lys and is later
removed by means of 2% trifluoroacetic acid (TFA) when the pep-
tide is still anchored to the resin. Then, the 1,2-HOPO-4-COOH
derivative is incorporated, followed by final global deprotection
and cleavage of the peptide from the resin (Scheme 1).
In addition to the carboxylic group, 1,2-HOPO-4-COOH (2) con-
tains a reactive N-hydroxy moiety (Fig. 1). N-Hydroxy derivatives,
such as HOPO,[5] ethyl cyanohydroxyiminoacetate (OxymaPure)
[11], 1-hydroxy-benzotriazole (HOBt)[12], and N-hydroxysuccin-
imide (HOSu)[13], are additives used in carbodiimide-based cou-
pling reagents[5]. These derivatives react with the O-acylisourea
formed by the reaction of the carboxylic group with the carbodi-
imide to render the active ester, which is the main acylating spe-
cies. Thus, the presence of this N-hydroxy in 1,2-HOPO-4-COOH
(2) could interfere with the activation of the carboxylic group
and posterior acylation. However, it could also act as an internal
additive favoring this reaction. Therefore, the first question to be
addressed is whether 1,2-HOPO-4-COOH (2) can be used without
masking the N-hydroxy group and whether it is necessary to use
an extra amount of additive such as OxymaPure to enhance cou-
pling, as the N-hydroxy of 1,2-HOPO-4-COOH (2) could be autocon-
sumed, forming a kind of 1,2-HOPO-4-COOH (2) oligomer
anchored to the peptide resin. These oligomers should not appear
as impurities in the final peptide because the bond between the
different monomers should be an active ester, which can be broken
by treatment with piperidine. However, the infertile consumption
of 1,2-HOPO-4-COOH (2) will be translated into poor
incorporation.Scheme 1. Synthetic strategy for the preparation of 1,2-HOPO containing peptides.
41The synthetic strategy for the introduction of 1,2-HOPO-4-
COOH (2) showed in Scheme 1 was applied, first, to the simple
model Ac-F-K-A-resin, (for characterization of the initial peptide,
see S1, S2, SI). 1,2-HOPO-4-COOH (2) (1.5 eq.) was introduced with
only N,N’-diisopropylcarbodiimide (DIC) (1.5 equiv) in DMF for
90 min, followed by piperidine treatment before cleavage the free
peptide (4, Fig. 2) from the resin. HPLC showed a conversion of 92%
(Fig. 2, A, the peak at 4.1 min corresponded to the unreacted pep-
tide). The reaction was then repeated, but in the presence of Oxy-
maPure (2 eq.). Surprisingly, the conversion was lower, only 81%
(Fig. 2, B). The reaction in the presence of OxymaPure was then
repeated, but a re-coupling step was carried out, with just half
the reagents, and without the final piperidine treatment. As
expected, the conversion was superior, but a small peak (5.7%)
with a higher retention time (5.8 min), which tentatively could
be assigned to an extra incorporation of the HOPO derivative on
the HOPO residue, was observed (Fig. 2, C). Finally, this experiment
was repeated (re-coupling), but the piperidine treatment was again
introduced into the synthetic process, resulting in the highest pur-
ity (95%) of the whole series, with the disappearance of the peak at
5.8 min (Fig. 2, D) (for characterization Fig. S3, SI). The first conclu-
sion from this simple model is that 1,2-HOPO-4-COOH (2) can be
incorporated without masking the N-hydroxy group. Given the cost
of the HOPO derivative and although the re-coupling renders a bet-
ter result, a single coupling could be appropriate for simple models.
Furthermore, the use of piperidine treatment is recommended as
an extra step in the synthetic process for removing the over incor-
poration of the HOPO derivative.
The Ac-K-K-K-S(tBu)-S(tBu)-resin, which has three Lys residues
in a row and mimics the sequence of natural siderophores, albomy-
cins,[14] was used in this study (for characterization of the initial
peptide S4-S5, SI). In this case, using similar conditions to those
of the experiment shown in Fig. 2A (single coupling using 1.5 eq.,
but for 3 h instead of 90 min), HPLC showed that all the starting
product (2.1 min, see S6, SI) had been consumed and that coupling
over the three e-amino groups (5, Fig. 3) took place with a yield of
39% (Fig. 3, A; for characterization Figure S7-S9, SI). Peaks at 4.5–
5.0 and 5.5–6.0 min corresponded to coupling over one and two
e-amino groups, respectively (for characterization Figure S7 and
S8, SI). A second coupling for 3 h was then performed using
0.33 eq. of reagents. The purity achieved with this approach was
slightly greater (44%, Fig. 3, B). Finally, a double coupling protocol
with 1.5 eq. for the first and 0.75 equiv. for the second was done,Fig. 2. Comparison of the HPLC crudes after the incorporation of unprotected 1,2-
HOPO-4-COOH to the Ac-F-K-A-resin. Method 5–95% B in A over 15 min. See
experimental part and SI for full HPLC conditions and characterization.
Fig. 3. Comparison of the HPLC crudes after the incorporation of unprotected 1,2-
HOPO-4-COOH to Ac-K-K-K-S(tBu)-S(tBu)-resin. Method 0–50% B in A over 15 min.
See experimental part for full HPLC conditions and SI for characterization). Fig. 4. HPLC analysis of A) the crude product (7) after acylation of the Ac-K-K-K-S
(tBu)-S(tBu)-resin with Bzl N-hydroxy protected 1,2-HOPO-4-COOH (6) and cleav-
age from the resin with TFA-TIS-H2O (95:2.5:2.5), method 5–95% B in A over
15 min.; B) the same but after the cleavage with TFMSA-TFA-TIS (3:8:1), to obtain 5,
method 0–50% B in A over 15 min. See experimental part and SI for the full HPLC
conditions and characterization.
D. Al Shaer et al. / Tetrahedron Letters 61 (2020) 152299 3which rendered a purity of 60% (Fig. 3, C). Of note, although the
results were not outstanding, the target product can be easily puri-
fied as the impurities were far away from the main peak, as shown
by HPLC.
Attempts to optimize this reaction at different temperatures
were made, as well as using a mixture of DMF and CH3CN as sol-
vent. However, these approaches did not give better results than
those reported above (Figure S10, SI).
Finally, the use of N-hydroxy protected 1,2-HOPO-4-COOH was
explored. In the literature, only Raymond’s[15] and Tetard’s [7,10]
laboratories have described synthetic procedures involving pro-
tected 1,2-HOPO, the benzyl (Bzl) group being the only one used
for this purpose. However, the conditions reported for the removal
of Bzl were not friendly (in solid-phase: 0.1 M BBr3 in DCM for
60 min,[16] 10% HBr in AcOH for 14 h;[17] in solution: 1 M BCl3 in
DCM for 2 d,[18] 50% HCl in AcOH for 4 d,[10]). Therefore, the syn-
thesis of other protected derivatives such as phenacyl and tetrahy-
dropyranyl was attempted but resulted unsuccessful in our hands.
Then, the use of the Bzl as protecting group was investigated.
Thus, 1,2-HOPO-4-COOH was reacted with BzlBr in the presence
of K2CO3 in MeOH as previously reported[17] and the product
was obtained in a 68% yield. The 1,2-HOPO(Bzl)-4-COOH (6)
(1.5 eq.) was reacted with the Ac-K-K-K-S(tBu)-S(tBu)-resin, in
DMF for 90 min using DIC (1.5 eq.). The cleavage carried out with
TFA-triisopropylsilane (TIS)–H2O (95:2.5:2.5), which kept the
HOPO residue protected, showed that total conversion of the start-
ing product and the purity of the protected HOPO(Bzl) peptide (7)
was 69% (Fig. 4, A). Finally, the unprotected HOPO peptide (5) was
obtained with a purity of 62% by cleavage with trifluoromethane-
sulfonic (TFMSA)-TFA-TIS (3:8:1) at room temperature for 70 min
(Fig. 4, B) —conditions used as an alternative to anh. HF in the
tert-butoxycarbonyl (Boc)-Bzl SPPS strategy to release the unpro-
tected peptides[19–20]. By comparison with the chromatogram
of Fig. 3, the peaks at 4.5–5 and 5.5–6 min were tentatively
assigned to those derivatives containing one or two residues of
1,2-HOPO, respectively.
Although the purity of the final product obtained from the Bzl
protected 1,2-HOPO-4-COOH was slightly greater than that pre-
pared from the unprotected HOPO derivative (62% vs 60%)
(Fig. 4-B vs. 3-C), the use of the former could be most cost effective,
because it avoids a protection step involving an expensive raw
material. Furthermore, some care should be taken when using
TFMSA in the laboratory to unmask the HOPO derivative.42Conclusions
The chelating effect in most of the metal-chelators, which show
applications in therapy and diagnostics, is achieved because of the
presence of three units of catechols, a-hydroxy carboxylic deriva-
tives, and/or hydroxamic acids. The chelators offer the ‘‘hard” elec-
tron donating oxygen atoms to strongly bind with ‘‘hard” metal
cation, such as Fe3+. 1,2-HOPO-4-COOH (2) is a commercially avail-
able compound that fulfils these characteristics, by having the N-
hydroxyl and the adjacent carbonyl as the binding moiety. Here,
we have described two friendly strategies for the Solid-Phase Pep-
tide Synthesis of 1,2-HOPO-containing peptide chelators. The first
involves the use of unprotected 1,2-HOPO-4-COOH (2), while that
the second uses the protected Bzl N-hydroxy (6). The use of unpro-
tected HOPO could be useful for the synthesis of most molecules,
which is beneficial due to the high cost of the building block. On
the other hand, if a Bzl protected HOPO derivative is being used,
we propose a friendlier protocol for removing the protecting group
than those reported in the literature,[10,16–19] namely the addi-
tion of TFMSA to the cocktail used for global deprotection and
cleavage of the peptide from the resin. The convenient SPPS strate-
gies described herein for the preparation of peptide chelators
should fuel further investigation in the field.Experimental part
Materials
All reagents and solvents were from commercial suppliers and
used without further purification. Fmoc amino acids and Fmoc-
Rink Amide AM PS resin (loading 0.74 mmol/g) were purchased
from Iris Biotech GMBH (Marktredwitz, Germany). DIC and Oxy-
maPure were a gift from Luxembourg Biotech. (Ness Ziona, Israel),
and N,N-diisopropylethylamine (DIEA) and piperidine were sup-
plied by Sigma-Aldrich (St. Louis, Missouri, USA). Organic solvents
[DMF, CH2Cl2 (DCM)] and HPLC quality acetonitrile (CH3CN) were
purchased from SRL (CRD-SRL, India). Milli-Q water was used for
RP-HPLC analyses. Analytical HPLC was performed on an Agilent
1100 system using a Phenomenex AerisTMC18 (3.6 lm,
4 D. Al Shaer et al. / Tetrahedron Letters 61 (2020) 1522994.6 150 mm) column, with flow rate of 1.0 mL/min and UV detec-
tion at 220 nm. Chemstation software was used for data process-
ing. Buffer A: 0.1% TFA in H2O; buffer B: 0.1% TFA in CH3CN. LC-
MS were performed on two systems: Shimadzu 2020 UFLC-MS,
column YMC-Triart C18 (5 mm , 4.6  1150 mm) column, 30 C (sys-
tem 1), an UltimateTM 3000, AerisTM 3.6 mm Wide pore column,
Phenomenex C18 (4.6 mm x150) column (system 2). In both sys-
tems were used Buffer A: 0.1% formic acid in H2O; buffer B: 0.1%
formic acid in CH3CN, flow 1.0 mL/min, UV detection 220 nm.
Solid-Phase peptide synthesis
Peptides were synthesized manually using a syringe fitted with
a porous polyethylene disc and attached to a vacuum trap for easy
filtration. Fmoc-Rink-amide-PS resin (100 mg, 0.74 mmol/g load-
ing) was taken and swelled in DMF (1 mL) for 15 min. Washings
before and after Fmoc removal and coupling were carried out with
DMF (1 mL). Fmoc removal was carried out with piperidine-DMF
(2:8) (3 mL 1 min + 7 min). Couplings were achieved by dissolving
the Fmoc-aa-OH (3 eq.) in the minimum amount of DMF. Oxyma-
Pure (3 eq.) and DIC (3 eq.) were then added sequentially, and the
mixture was left to pre-activate for 3 min. The resulting solution
was added to the resin in the syringe and allowed to couple for
1 h with sporadic stirring. Acetylation of the N-termini was
achieved by adding DIEA (20 equiv.) to the swelled peptide resin,
followed by addition of acetic anhydride (Ac2O) (10 equiv.). The
resin was then allowed to react for 30 min. with occasional stirring.
Mtt deprotection was done using TFA-TIS- DCM (2:5:93) (3 mL for
2  2 min. + 1  15 min.).
1,2-HOPO-4-COOH incorporation: After removal of the Mtt
group, the resin was treated with DIEA-DCM (1:19) (3 mL,
3  1 min) and then washed with DMF. The corresponding equiv.
of 2 or 6, and OxymaPure (1 equiv. respect 2), if required, were dis-
solved in the minimum amount of DMF and added to the peptide
resin. Then, DIC (1 eq with respect to 2) was added to the mixture
and left to react for 90 min. The resin was washed with DMF.
Global deprotection and cleavage was performed by adding
TFA-TIS-H2O (95:2.5:2.5) or TFMSA-TFA-TIS (3:8:1) (500 mL) per
50 mg of the peptide resin for 70 min.at RT. In the first case, the
crude peptide was precipitated with diethylether, isolated by cen-
trifugation, dried under vacuum and then dissolved in H2O, and
lyophilized. While after the TFMSA cleavage, the filtrate was col-
lected over H2O (2.0 mL) and the precipitate was isolated by cen-
trifugation, washed with diethyl ether, dissolved in H2O, and
lyophilized.
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1,2-HOPO containing peptides were synthesized on solid-phase by derivatization of Lys side chain 
residues once the peptide chain was fully elongated. This derivatization was done in two different
routes, the first route uses the free form (no N- OH protection) of 1,2-HOPO-4-COOH (peptides 1 and
2, Fig. 2 ). The second route uses the Bzl protected N-OH form of 1,2-HOPO-4-COOH as it is commonly
reported in the literature (peptide 3, Fig. 2 ). Peptide 1 was obtained in a very good purity, while
peptide 2 was obtained in lower but acceptable purity and, very importantly, very easy to be purified.
This is due because the main impurities containing only two or one incorporation of 1,2-HOPO-4-
COOH moieties, appeared in the HPLC far away of the target peak. In peptide 3, the removal of
the Bzl groups is carried out during the global deprotection and cleavage of the peptide from the
resin using a friendlier condition [TFA- TFMSA-H 2 O (8:3:1)] than those reported in the literature.
Scheme 1 describes all the synthetic steps of both routes for the synthesis of the peptides. 
The different steps are: 
(I) Peptide backbone elongation on solid support 
(This step was performed following a standard Fmoc/tBu strategy protocol. 0.1 mmol of the peptide
will be prepared following these steps: 
Chemicals and apparatus 
Caution: You should perform steps I-IV in a fume hood wearing a protective coat, goggles, and gloves. 
Fmoc-Rink-amide-AM-PS-resin (Loading: 0.7 mmol/g, Iris Biotech, 20 0-40 0 mesh) Fig. 1. (a) 1,2-HOPO (b) 1,2-HOPO-4-COOH (c) General structure of a hydroxamic acid. 
Fig. 2. Peptides synthesized containing 1,2-HOPO moieties. 
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N α-(9-Fluorenylmethoxycarbonyl) amino acids: Fmoc-Ala-OH, Fmoc-Lys(Mtt)-OH, Fmoc-Phe-OH
(for peptide 1), and Fmoc-Ser(tBu)-OH, Fmoc-Lys(Mtt)-OH for peptide 2 and 3. Mtt:
methyltritryl, tBu: tert-butyl, Iris Biotech. 
N,N’-Diisopropylcarbodiimide (DIC) (Luxembourg Bio Technologies. Be careful !!, it is flammable
and irritant) 
OxymaPure (Luxembourg Bio Technologies) 
Acetyl chloride (AcCl) Sigma-Aldrich, Be careful !!, it is flammable and corrosive) 
N,N-Diisopropylethylamine (DIEA) (reagent grade 99%, Sigma-Aldrich, Be careful !!, it is flammable
and corrosive) 
Piperidine (reagent grade 99%, Sigma-Aldrich, Be careful !!, it is flammable, corrosive and toxic) 
N,N-Dimethyl formamide (DMF) (extra pure AR grade, SRL, Be careful !!, it is flammable, harmful
and health hazard) 
Analytical balance (Mettler Toledo) 
5 mL polypropylene syringe fitted with a polypropylene preinserted frit (20 μm). 
Vacuum manifold (Vac-Man® Laboratory Vacuum Manifold, Promega) ( Fig. 3 ) 
Vacuum pump 
Procedure 
1. Prepare the syringe fitted with a polypropylene filter. 
2. Weigh Fmoc-rink-amide-AM-PS-resin (143 mg for 0.1 mmol synthesis scale) and place it in the
syringe. 
3. Place the syringe on the manifold (as in Fig. 3 ) and adjust the suction (you only need a gentle
suction). 
4. Wash the resin with DMF (1 min, 1 mL) and drain the solvent over gentle vacuum, repeat it
twice. 
5. Add DMF (3 mL) and allow it to swell the resin for about 15 min. This step will make the active
sites of the resin to be accessible for the reactants in the following steps . 
6. Meanwhile, in separate glass vials, weigh 0.3 mmol (3 eq. with respect to the resin). of each
the Fmoc-AA-OH required to build the peptide chain. [To prepare peptide 1, Fmoc-Ala-OH:
93.4 mg, Fmoc-Lys(Mtt)-OH:187.4 mg, and Fmoc-Phe-OH:116.2 mg,. To prepare peptides 2 and
3, 2x Fmoc-Ser(tBu)-OH:115 mg, and of 3x Fmoc-Lys(Mtt)-OH187.4 mg, for each peptide]. 
7. Add (43 mg, 0.3 mmol) of OxymaPure to each Fmoc-AA-OH vial. This additive will form the
corresponding active ester after that the Fmoc-amino acid has been activated with DIC see step
#12, modulating the reactivity to minimize early hydrolysis and/or side-reaction formation. See ref
[ 7 ] for a better understanding of the mechanism of the reaction . 47
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Scheme 1. Synthesis of 1,2-HOPO-containing peptides using both strategies. Blue arrows represent the steps that were 











8. To remove the Fmoc protecting group, prepare a 20% solution of piperidine in DMF. It is not
necessary to prepare freshly this solution. Once per week is advisable, keep it a dark glass bottle. 
9. Once the resin is well swollen, filter off the solvent and start the synthesis. 
10. Add the piperidine solution (1 mL) to the resin, stir for 1 min and drain the solution off. Add
again 1 mL of the piperidine solution and stir for 7 min, then filter and wash with DMF (3 × 1
ml). 
11. Dissolve the mixture of Fmoc-AA-OH/OxymaPure corresponding to the residue to be incorporate 
(be aware that the peptide synthesis starts by the C-terminal end of the sequence). It is
advisable to use the minimum amount of DMF for dissolving the mixture but should be enough
to cover the swollen resin (for 143 mg of this kind of resin, approx. 600 μL are needed). 
12. To the previous mixture solution, add the coupling reagent, DIC (47 μL, 0.3 mmol) and allow
the activation for 2 min. The active ester is formed. More time could conduct to the hydrolysis of
the ester and/or epimerization. 
13. Transfer the solution to the drained resin in the syringe (after Step 10), make sure all resin
beads are covered with the solution, add few more drops of DMF if needed. 
14. Leave the slurry to react for 40-60 minutes with occasional stirring. The course of the reaction
could be confirmed by the ninhydrin test. 
15 Drain the solution, wash with DMF (1 mL, 30 sec.) with stirring, drain it, and repeat the
washing for two more times. 
16. Repeat Steps 8–15 for each amino acid in the sequence. 
17. Proceed to Step 10 to remove the last Fmoc protecting group. 48












18. To acetylate the N-terminal of the prepared peptide, add DIEA (345 μL, 20 mmol), then AcCl
(95 μL, 10 mmol), shake it for 30 min., drain the solution and wash with DMF (3 × 1 mL). 
(II) Protecting the N-OH of 1,2-HOPO-4-COOH [1,2-HOPO(Bzl)-4-COOH] 
This step was done following with slight modifications the procedure reported in literature for
other 1,2-HOPO derivative [8] . 
Chemicals and apparatus 
4-Carboxy-1-hydroxypyridin-2-one (1,2-HOPO-4-COOH) (ChemSpace) 
Benzyl bromide (BzlBr) (Sigma-Aldrich) 
Potassium carbonate (K 2 CO 3 ) (Sigma-Aldrich) 
Methanol (MeOH) (Laboratory reagent > 99.6%, Sigma-Aldrich) 
6 M HCl 
Ice 
Round bottom flask 
Condenser 
Oil bath 
Hotplate and stirrer 
Rotatory evaporator 
Procedure 
1. In a round bottom flask with a magnetic stirrer, weigh 1,2-HOPO-4-COOH (155 mg, 1 mmol)
and K 2 CO 3 (268 mg, 2 mmol). 
2. Add 10 mL of MeOH and place the round bottom flask in an oil bath. 
3. Stir the suspension and add BzlBr (143 μL, 1.2 mmol) drop wise over 1 min. 
4. Attach the condenser, and reflux the mixture at 65–70 °C for 16 h. 
5. Remove the MeOH under reduced pressure in a rotatory evaporator. 
6. Dissolve the residue with H 2 O (5 mL). If does not readily dissolve add few drops of 1M NaOH. 
7. Acidify the aqueous solution with HCl (6 M) dropwise to pH 2, a white precipitate should
heavily form. 
8. Filter the precipitate, wash it with ice-cold water, and dry it under vacuum. 
9. Characterize the product using NMR, analytical HPLC and LCMS. The yield is about 70%. 
(III) Incorporation of HOPO (protected and unprotected) to the peptide 
Chemicals and apparatus 
Peptidyl resins prepared in part I (Ac-F-K(Mtt)-A-NH-Rink-amide-resin and Ac-K(Mtt)-K(Mtt)-
K(Mtt)-S(tBu)-S(tBu)-NH- Rink-amide-resin) 
1,2-HOPO-4-COOH (ChemSpace). 
1,2-HOPO(Bzl)-4-COOH (prepared in II) 
N,N-Diisopropylcarbodiimide (DIC) (Luxembourg Bio Technologies. Be careful !!, it is flammable
and irritant) 
N,N-Dimethyl formamide (DMF)) (extra pure AR grade, SRL, Be careful !!, it is flammable, harmful
and health hazard) 
Trifluroacetic acid (TFA) (reagent grade 98%, Sigma-Aldrich. Be careful !!, it is corrosive and
harmful) 
Triisopropyl silane (TIS) (Reagent grade98%, Sigma-Aldrich. Be careful !!, it is flammable). 
Dichloromethane (DCM) (ACS reagent > 99.9%, Honeywell. Be careful !!, it is harmful and health
hazard). 
Diisopropylethylamine (DIEA) (reagent grade 99%, Sigma-Aldrich. Be careful !!, it is flammable and
corrosive) 
5 mL polypropylene syringe fitted with a polyethylene filter 
The solid phase peptide set up mentioned in section I ( Fig. 3 ). 
Procedure 
1. Place the peptide resin in the syringe, place it on the manifold and wash it with DCM
(3 × 1 mL) 49



















2. To remove Mtt protecting, prepare a solution of TFA-TIS-DCM (3:5:92) (300 μL TFA, 500 μL TIS,
9.2 mL DCM). 
3. Add 2 ml of the TFA solution to the peptide resin and shake it for 15 min. Evolution and
disappearance of yellow color is detected, which indicates the release of the Mtt carbocations and
its posterior scavenging . 
4. Filter off the solution. Wash the resin with DCM (3 × 3 mL) for 30 sec. 
5. Repeat Steps 3 and 4 for one more time. 
6. Wash the resin with 5% DIEA in DCM solution (3 × 1 mL). The DIEA treatments is to liberate the
free amine of the Lys. 
7. Wash the resin with DCM (3 × 1 ml), then with DMF (2 × 1 mL), the peptide resin is now
ready for the incorporation of 1,2-HOPO-4-COOH, unprotected and protected. 
8. a) Unprotected: dissolve 24 mg (0.15 mmol) of 1,2-HOPO-4-COOH per each Lys to be derivatized,
in 600 μL of DMF; 
b) Protected: dissolve 37 mg (0.15 mmol) of Bzl protected 1,2-HOPO-4-COOH per each Lys to be
derivatized, in 600 μL of DMF. 
1. Transfer the HOPO solution to the resin, then add DIC (24 μL, 0.15 mmol per Lys), shake for
90 min, drain the solution off, then wash with DMF (3 × 1 mL). 
2. An optional second coupling can be done using less equivalents of HOPO and DIC to increase
the yield (as in Table 1 ). But as 1,2-HOPO-4-COOH is rather expensive, this step can be avoided.
3. In case of using the unprotected HOPO (in peptides 1 and 2), treat the peptidyl resin with 1 mL
of 20% piperidine in DMF solution for 10 min. ( To remove any ester oligomers that may have
formed through the N-OH). Wash the resin with DMF (3 × 1 mL) 
4. Wash the resin with DCM (3 × 1 mL). 
(IV) Cleaving the peptide from the resin 
Chemicals and apparatus 
Peptide resins prepared in part III (Ac-F-K(HOPO)-A-NH-resin, Ac-K(HOPO)-K(HOPO)-K(HOPO)- 
S(tBu)-S(tBu)-NH-Rink-amide-resin and Ac-K(HOPO-Bzl)-K(HOPO-Bzl)-K(HOPO-Bzl)-S(tBu)- 
S(tBu)-NH-Rink-amide-resin) 
Trifluoromethanesullfonic (TFMSA) (reagent grade 98%, Sigma-Aldrich. Be careful!!, it is corrosive 
and harmful) 
Trifluroacetic acid (TFA) (reagent grade 98%, Sigma-Aldrich. Be careful !!, it is corrosive and
harmful) 
Triisopropyl silane (TIS) (Reagent grade98%, Sigma-Aldrich. Be careful !!, it is flammable). 





5 mL polypropylene syringe fitted with a polyethylene filter 
Falcon tube 
Two cleavage mixtures were used: 
Mixture A (TFA-TIS-H 2 O, 95:2.5:2.5) to cleave peptide from resin and to remove the acid labile
protecting groups, namely, tBu from the Ser side chain (and leaving the Bzl unaffected if it is
present) (this mixture was used for all peptides). 
Mixture B (TFA-TFMSA-TIS, 8:3:1) to cleave the peptide from the resin and to remove all other
protecting groups including the Bzl (this mixture was used to get peptide 2 from peptide resin
3). 
Procedure 
1. Place the peptide resin in the syringe and wash it with MeOH and dry under gentle suction. 
2. Weigh the resin and transfer it into a falcon tube fitted with a cap. 50
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Table 1 
Purities and yields for the prepared peptides, 1-3. 




Purity % Yield 
1 Free N-OH Mixture A 92% for single 
coupling (1.5 eq) 
97% for double 
coupling (1.5 eq, 
then 0.75 eq) 
88% crude peptide 
2 Free N-OH Mixture A 39% for single 
coupling (1.5 eq 
per Lys) 
60% for double 
coupling (1.5 eq 
per Lys, then 0.75 
eq per Lys) 
87 % crude peptide 
3 N-OBn Mixture A 69% 71 % crude peptide 
2 from 3 N-OBn Mixture B 62% 63 % crude peptide 

















3. Add the cleavage mixture (1 mL/100 mg peptidyl resin), close the cap and shake the tube for
70 min. 
For mixture A : 
1. Add ice-cold diethyl ether (5 mL/1 mL cleavage mixture), shake well (the peptide will
precipitate), centrifuge the mixture and decant the supernatant, repeat the ether washing for
two more times. Do not discard the diethyl ether washing till you get your peptide at the end. 
2. Dry the residue under reduced pressure, add water (3 mL) to dissolve the peptide. 
3. Filter off the resin beads and keep the filtrate. 
4. Wash the resin beads two more times with (1 mL) water each, filter and combine all filtrates. 
5. Lyophilize the peptide solution. 
For mixture B 
1. Add water (5 mL/1 mL cleavage mixture). 
2. Wash the aqueous layer with diethyl ether (5 mL). 
3. Remove the ether layer and repeat the washing 2 more times. 
4. Filter off the resin beads. 
5. Lyophilize the aqueous filtrate. 
(V) Purification and Characterization 
ll peptides were purified using reversed phase semi preparative HPLC, the pure fractions were
yophilized and stored at 4 °C. All peptides were obtained in good yields. They were characterized
sing analytical HPLC and LCMS techniques. Purities of peptides were determined by comparison of
eak area for each peptide in the HPLC chromatogram at 220 nm. Yields were determined from the
ass of the lyophilized peptide in relation with the theorical mass (see Table 1 ). 
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Abstract: 
Hydroxypyridones (HOPO) are an important class of chelating compounds. They bind strongly to hard 
metal ions such as Fe (III). Here we present the solid-phase synthesis of peptides containing 1,2-HOPO 
moieties linked through a carboxylic acid placed at 4-position of the ring.  A total of four ligands have 
been studied, two bidentate and two hexadentate. The last have been synthesized by two different 
strategies, stepwise and convergent. The Physiochemical characterization of ligands and their 
complexes have been carried out. The determined pKa values for all ligands showed their total 
deprotonation at pH lower than the physiological. The determined formation constant of the Fe(III) 
complex (log β) were from 23.66, corresponding to ligand A,  to 27.63 corresponding to ligand C. When 
the pFe3+ at pH=7.4 were calculated the result showed that ligands B and C had a strong iron affinity 
(26.91 and 28.58, respectively) which make them suitable for further investigation in therapeutic 
applications. 
1. Introduction: 
Iron is essential for almost all living organisms to transport oxygen, to produce energy, as a nutrient, 
and as part of the metabolic process.  To address their iron needs, microorganisms such as bacteria and 
fungi produce siderophores, which in Greek means iron carriers.  The main characteristic of the 
siderophores is its high affinity towards Fe(III) [1, 2].  Through this mechanism, microorganisms 
scavenge Fe(III) from the environment and assures their survival.  From a chemical point of view, most 
part of the siderophores contain O,O’ bidentate chelate, which can be mostly derived from catechols, 
α-hydroxy carboxylic acids, or hydroxamic acids [3, 4].  Most of the natural siderophores contains three 
of these bidentate chelate making them hexadentate chelators.  In some of them, there are only one class 
of the chelate, while very often mixture of them is present [4, 5].   
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In addition of Fe(III), hydroxamic acids also show high binding affinities in front of a broad range of 
transition metals.  This capacity has fuelled its further application in another scientific areas such as 
metal scavenging or as radiopharmaceuticals [6-8] .    
Many reported synthetic Fe (III) chelators are based on hydroxypyridinones (HOPO), a pyridine 
heterocycle with carbonyl and hydroxy substituents [9-12]. For siderophore purposes, they can exist in 
the forms of 1-hydroxypyridine-2-one (1,2-HOPO), 3-hydroxypyridine-2-one (3,2-HOPO), and 3-
hydroxypyridine-4-one (3,4-HOPO) (Figure 1). 1,2-HOPO is the only one that is a hydroxamic acid, 
and therefore has the lower pKa among this family (Figure 1) [13].  1,2-HOPO is deprotonated at 
physiological pH, which could be an advantage thinking in medicinal chemistry terms.  This does not 
happen in the aliphatic hydroxamic acid derivatives, which are present in the natural siderophores.  
 
Figure 1. Representative structures of different HOPOs, n-Hydroxypyridine-m-one, n:1, 3, m:2, 4. 
To incorporate these moieties in an organic scaffold, an additional functionality is needed.  In this 
regard, two commercially available carboxylic acid derivatives of 1,2-HOPO, in position 4 and 6 [4/6-
carboxy-1-hydroxypyridin-2-one (1,2-HOPO-4-COOH/1,2-HOPO-6-COOH)], can facilitate its 
incorporation into an organic scaffold or other biological molecule of interest.  
To facilitate the preparation of HOPO containing peptides and study their Fe(III) binding, we have 
previously reported a method to synthesize these molecules on solid phase support using 1,2-HOPO-4-
COOH (Figure 1), which is incorporated  with the OH unmasked to the ε-amino function of the Lys, 
resulting in a very convenient synthetic strategy [14, 15].  
In this work we describe three ligands (A, B, and C) containing 1,2-HOPO binding units anchored to 
peptide through 1,2-HOPO-4-COOH.  Furthermore, the carboxamide derivative of the binding unit 1,2-
HOPO-4-COOH (Y) has been also included in the study (Figure 2).  The ligands vary in denticity, two 
bidentates (A, Y) and two linear hexadentate (B, C) chelators.  The solution thermodynamic properties 
of the four ligands (A, B ,C, Y), as well as their Fe (III) complexes based on spectrophotometric methods 
are described herein.  This will give an indication of their potential application as therapeutic agents. 
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Figure 2. HOPO-containing ligands A, B, C and Y. 
 
2. Results and discussion 
2.1 Synthesis of the ligands 
Syntheses of A and B have been previously described in our earlier publication [14].  Their syntheses 
were carried out in a stepwise manner by incorporation of 1,2-HOPO-4-COOH to the peptide chain 
anchored to the resin after the selective deprotection of the ε-amino of the Lys. Y was obtained by 
amidation of 1,2-HOPO-4-COOH.  
Ligand C is prepared by a convergent approach where a small unit of β-Ala-Cys having the 1,2-HOPO 
at the N-terminal and the free thiol of the Cys is incorporated in solution to the peptide having 
maleimido moieties anchored to the three Lys of the peptides (Scheme 1).   Ligand A, B, and C have 
their N-terminus acetylated to prevent any possible interference in Fe(III) chelation.   
Units 3 and 6 have been prepared on Rink-amide-resin using Fmoc/tBu based SPPS techniques. Thus, 
1,2-HOPO-4-COOH was incorporated to the H-βAla-Cys(Trt)-NH-Rink-amide-resin (2) using N,N’-
diisopropylcarbodiimide (DIC) as activating agent, without protection of the N-OH as previously 
described by our group [14] (Scheme 1).  After the cleavage of the resin with trifluoracetic acid (TFA)-
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triisopropylsilane (TIS)-H2O (95:2.5:2.5), which also remove the Trt (trityl) of the Cys side-chain, the 
free thiol peptide (3) was purified by semi-preparative HPLC.  
Using the same strategy, Ac-Lys(Mtt)-Lys(Mtt)-Lys(Mtt)-βAla-NH-Rink-amide resin (4) was 
prepared.  The Mtt (methyltrityl) of the ε-amino of the Lys was selectively removed using 2% 
trifluoroacetic acid (TFA) in dichloromethane (DCM). Treatment with 5% N,N-diisopropylethylamine 
(DIEA) in DCM liberates the free amines, which were acylated with 6-maleimidohexanoic acid with 
HBTU and DIEA. Peptide 6 was cleaved from the resin as before and purified by semi-preparative 
HPLC.  
Conjugation of peptides 3 and 6 was smoothly performed through a thiol-ene Michael addition of 
peptide 3 containing the free thiol on the maleimido moieties of peptide 6 at pH 6.5 which avoid the 
dimerization on the thiol-peptide (Scheme 1).  Although this kind of reactions renders high purity 
products and usually desalting is only required, Ligand C was purified by semi-preparative HPLC for 
ensuring the highest purity for the subsequent physico-chemical determination. 
 
 
Scheme 1.  Preparation of Ligand C. 
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2.2 Physiochemical characterization of ligands and their complexes 
The calculation of the ligand’s affinity towards Fe (III) requires the determination of the acid 
dissociation constants of all ligands (pKa) as well as the formation constants of their complexes with 
Fe (III) (log βMLH).   The pKa’s were determined by spectrophotometric titrations and the log βMLH by 
solution competition with the well-known strong metal chelator ethylenediaminetetraacetic acid 
(EDTA). 
Bidentate ligands are expected to form an FeL3 complexes, and FeL for hexadentate. Since our ligands 
are peptide-based and they contain other functional groups (acetylated N-terminals as well as hydroxyl 
groups of the Ser in ligand B), we first performed an experiment to determine the stoichiometry of each 
ligand’s complex.  
 
2.2.1 Ligand-Fe (III) complex stoichiometry determination 
The stoichiometry of Fe(III) complexes of each ligand was determined by UV-absorption. A serial 
solutions (methanol as solvent) in which the ligand concentration was constant with increasing 
concentration of Fe(III) were prepared. To ensure full deprotonation of the ligands (and consequently 
maximum complexation) a mild base 2,6-Lutidine was added in a small excess with respect to the 
ligand. In all cases, the range of Fe(III) concentration added was from 0 to the double amount required 
to form complexes 1:3 (bidentate ligands) and 1:1 (hexadentate ligands). All mixtures gave pale yellow 
colour corresponding to the Fe-HOPO complexes. First, the spectra of the solutions containing only 
Fe(III), only the ligand, and the mixture of both were recorded in a range of  280-700 nm. These spectra, 
allowed to select the best wavelength to study the complex formation. All the complexes showed a 
weak broad absorption peak in the range of 400-550 nm with no interferences because the absorption 
of the free ligand or Fe(III) solution (Fig.3). For further plots, absorbances at 460 nm for ligand Y, 480 
nm for ligands A and B and 450 nm for ligand C were chosen. 
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Figure 3.  Comparison of UV-visible spectra of Fe (III), and: a) Ligand Y b) Ligand A c) Ligand B d) ligand C, 
and one representative L-Fe mixture. 
The complexes stoichiometry can be easily determined by plotting the absorbance at the selected 
wavelengths of the previously described solutions vs the different ratio concentration Fe/L (Fig. 4). The 
plots showed that initially there is an increase in the absorbance as the Fe(III) concentration is 
increasing. Then, a plateau is reached, no absorbance changes by adding Fe(III), which means that all 
the ligand is now forming the complex. The obtained ratios were, as expected, around 0.33 for the 
bidentate ligands Y and A (complex formula FeL3) and around 1 for the hexadentate ligands B and C 
(complex formula FeL). On base of these results, the rest of experiments as well as the evaluation of 
the thermodynamic constants were done using these ratios.   
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Figure 4. Plot of Absorbance vs [Fe (III)]/[Ligand X].  a) Ligand Y at 460 nm. b) Ligand A at 480 nm.  c) Ligand 
B at 480 nm d) Ligand C at 450 nm. 
 
2.2.2 Determination of pKa values 
The determination of pKa values of the ligands were carried out by spectrophotometrical titration. The 
UV spectra were recorded from 200 to 800 nm in a pH range from 2 to 11. In all cases a shift of λmax 
from values around 315 to values around 340 (depending on the ligand) were observed (Fig. 5). The 
data were analysed and refined using the program KEV [16]. 
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Figure 5.  Dependence of UV spectra on pH (I=0.1 M KCl) of 5.2 x 10-5 M solutions of a) Ligand Y, b) Ligand 
A, c) Ligand B, and d) Ligand C. The highlighted spectra correspond to starting solution and end of each titration. 
Full spectra (200-800 nm) are shown in the SI-Fig.8  
The pKa values obtained from non-linear least square regression analysis are shown in Table 1. These 
pKa values are consistent with values reported in the literature for similar compounds [9, 11, 17, 18]. 
The bidentate ligands Y and A have very close pKa values (5.29 and 5.25 respectively), being a little 
bit higher than the pKa value of 1,2-HOPO-6-COOH (5.17) [12],  and lower than 1,2-HOPO (5.8) [13]. 
For the hexadentate ligands B and C, the respective pKa values also are very close.  The low pKa values 
showed by all the ligands indicates that at physiological pH would be mainly in a deprotonated form, 
hence the competition of the protons for the iron complexation would be low. 
Table 1.  Proton dissociation constants for HOPO moieties in Ligands Y, A, B, and C. 
 Ligand Y Ligand A Ligand B Ligand C 
pKa1 
(log β13) 





















2.2.3 Iron (III) complexation 
The stability constants (log β) were determined by Fe (III) binding competition between the ligands and 
EDTA. To this end, solutions containing a fix amount of Fe(III) and the corresponding stoichiometric 
amount of ligand were prepared. Then, EDTA from 0 to 10 times the Fe(III) concentration was added 
and the solutions were equilibrating for 48 h. After that time the UV spectra were recorded (Fig.10). 
The spectra showed clearly the different behaviour of the bidentate ligands respect the hexadentate 
ligands. Whilst, the addition of EDTA made disappear the UV peak corresponding to the complex FeL3 
in case of ligand Y and A, the peak corresponding to FeL remained unaltered for ligands B and C. 
 
Figure 6.  UV-visible spectra of EDTA competition with a) Ligand A b) Ligand Y c) Ligand B d) Ligand C. 
where [Fe3+]=3.0x10-5 M, [L]B,C= 3.1x10-5 M, [L]A,Y= 9.3 x 10-5 M, [EDTA2-] from 6.2x10-6 M to 3.1x10-4 M. 
 
The spectral data were processed using the software KEV. For the calculations, the absorbance at λ=470 
nm for ligands Y, A, and B, and λ=420 nm for ligand C were used. Additionally, the pKa values of 
ligands obtained before, pKa value of EDTA, the reported formation constants values of FeEDTA2- [12], 






Table 2.  Complex formation constants and pFe3+ values for Ligands Y, A, B, and C 
Complex Log β13  pFe 
Fe(LY)3 24.05 14.59 
Fe(LA)3 23.66 14.19 
 
Log β110 pFe 
Fe(LB) 25,99 26,91 
 Fe(LC) 27,63 28.58 
*this work, pFe3+ values were calculated at pH=7.4, [L]=10-5, [Fe3+]=10-6M 
The log β values determined are in the expected range compared with the reported value for 
their parent compound, 1,2-HOPO ( log β3=26.9) [12]. When the pFe3+ values were calculated 
clearly the highest affinity corresponds to hexadentate ligands (C and D) in contrast to 
bidentate, due to the chelate effect. Iron complexes of ligands B and C showed affinities close 
to similar compounds reported in literature [11]. 
 
Figure 7. pH dependence of calculated pFe3+ values for ligands A,B,C and Y, under the conditions [chelator]= 
10-5M, [Fe3+]=10-6 M, compared to OH- (red thick line, the formation constants used for the calculations for the 


















        
        
        




Fe (III) chelators are important class of molecules that have found a vast range of applications in 
different fields, such as imaging, probes, or chelation therapy.  1,2-HOPO as Fe (III) chelating moiety, 
through 1,2-HOPO-4-COOH has been safely incorporated to peptide backbones.  We have 
demonstrated that 1,2-HOPO-4-COOH could be incorporated to the peptide through a SPPS scheme 
without protecting the N-OH.  Two routes have been developed.  The first one involves a direct 
acylation of side-chains of Lys, named stepwise strategy (ligand B) and the second one, convergent 
strategy (ligandC), involves the conjugation of two pre-synthesized moieties, one which contain the 
1,2-HOPO unit as well as a thiol function and a core bearing maleimide derivatives. From a synthetic 
point of view, both routes show pros and cons but allowed the preparation of 1,2-HOPO-peptides.  The 
four ligands included in this study, two bidentate (Y and A) and two hexadentate (B and C) form iron 
complexes, however the former ones showed low pFe3+ whilst ligands B and C showed a strong pFe3+. 
These results highlight the importance of being hexadentates ligands supported by a scaffold, in this 
case peptides which can improve the solubility or can be designed to facilitate the uptake.  Thus, we 
can conclude that this new family of 1,2-HOPO containing peptides are promising candidates to be 





All reagents and solvents were from commercial suppliers and used without further purification. Fmoc-
Rink-amide polystyrene resin and Fmoc-amino acids from Iris Biotech GMBH (Marktredwitz, 
Germany). OxymaPure was a generous gift of Luxembourg Bio Technologies (Ness Ziona, Israel). 1,2-
HOPO-4-COOH was purchased from Chemspace US Inc. (Monmouth Junction, New Jersey, USA). 
N,N-diisopropylethylamine (DIEA) and piperidine were supplied by Sigma-Aldrich (St. Louis, 
Missouri, USA). Organic solvents [DMF, DCM] and HPLC quality acetonitrile (CH3CN) were 
purchased from SRL (CRD-SRL, India). All other chemicals were purchased from Merck-Millipore 
(Burlington, Massachusetts, USA). 
Analytical HPLC was performed on an Agilent 1100 system using a Phenomenex AerisTMC18 (3.6 
μm, 4.6 x 150 mm) column, with flow rate of 1.0 mL/min and UV detection at 220 nm. Chemstation 
software was used for data processing. Buffer A: 0.1% TFA in H2O; buffer B: 0.1% TFA in CH3CN. 
LCMS were performed on a Thermo Scientific™ UltiMate™ 3000 Standard Binary System, ISQ™ EC 
Single Quadrupole.  Buffer A: 0.1% formic acid in H2O; buffer B: 0.1% formic acid in CH3CN, Flow: 
1.0mL/min., UV detection=220 nm, Column: Phenomenex Luna C18 3.6 μm, 4.6 × 150 mm column, 
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30  Cͦ.  UV spectra were recorded on two systems: 1) Impelen NP80 UV nano-drop spectrophotometer, 
2) Shimadzu UV-3600 using cuvettes with 10 mm path length. pH-measurements were done using 
Insmark pH-meter. Milli-Q water was used for RP-HPLC analyses as well as all physiochemical 
characterization experiments.  
 
Solid-Phase peptide synthesis 
Ligands A and B were synthesised as previously reported by our group [14]. Peptides were synthesized 
manually following the SPPS Fmoc/tBu strategy using a syringe fitted with a porous polyethylene disc 
and attached to a vacuum trap for easy filtration as follows. Fmoc-Rink-amide-resin (0.74 mmol/g) was 
placed in the syringe, swollen with 3 mL DMF for 15 minutes. The solvent was drained and 2 mL of 
piperidine-DMF (2:8) (3 mL 1 min + 7 min) drained and washed with DMF (x 3). To a premixed 
solution of the Fmoc-amino acid (3 eq.) and OxymaPure (3 eq.) in 600 uL DMF, DIC (3 eq.) was added 
and the solution was left to pre-activate for 2 minutes. The resulting solution was added to the resin in 
the syringe and allowed to react for 30 min. with sporadic stirring. The Fmoc removal, Fmoc-amino 
acid coupling steps were repeated for all amino acids in the sequence. 
Cleavage of the peptides from the resin was carried out with TFA-TIS-DCM (95:2.5:2.5, 500 μL/50 mg 
resin) for 1 hr.  The filtrates were added over cold ether and the precipitated was isolated by 
centrifugation.  Crude peptides were purified by semi-preparative HPLC and lyophilized purified.   
Synthesis of ligand C: 
HOPO- βAl -Cys-NH2 (3) 
The dipeptidyl resin H-βAla-Cys(Trt)-NH-resin (1) was prepared as described above.  Then, 1,2-
HOPO-4-COOH (1.5 equiv.) and DIC (1.5 equiv.) in DMF were added, and the mixture was left for 90 
min. with occasional stirring. The resin was washed with DMF(3x). After cleavage peptide 3 was 
obtained. (ESI-MS (m/z): 329.1 [M+H]+), and calculated 328.08 g/mol.  See SI for HPLC 
chromatograms. 
Ac-Lys(Mha)-Lys(Mha)-Lys(Mha)- βAl -NH2 (6)  
Acetylation of the last Lys residue was carried out by adding Ac2O (10 equiv.) and DIEA (20 equiv.) 
in DMF to the resin and left to react for 30 min with occasional stirring, and finally washed with DMF 
(3x). 
Mtt side-chain protecting group was removed from peptide resin (4) by TFA-TIS- DCM (2:5:93) (3 mL 
for 2 x 2 min. + 1 x 15 min), then it was washed with DCM, and with 5% DIEA in DCM to neutralize 
the ε-amine side chain. The resin was then washed with DCM and DMF before adding a solution of 6-
maleimidohexanoic acid (Mha, 9 equiv., 3 equiv. per Lys) in DMF followed by 3-
[bis(dimethylamino)methyliumyl]-3H-benzotriazol-1-oxide hexafluorophosphate (HBTU, 9 equiv.) 
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and DIEA (18 equiv.) coupling reagent, the mixture was stirred for 60 min. before being washed with 
DMF.  After cleavage, the crude was purified by semi-preparative HPLC and lyophilized to yield 
peptide 6. (ESI-MS (m/z): 548.13 [M+2H]2+), and calculated 1094.26 g/mol.  See SI for HPLC 
chromatograms. 
Ligand C 
Peptide 6 was dissolved in 1 mL of ACN and 4 mL of phosphate buffer (pH= 6.5) were added. Then, 
peptide 4 (3 equiv., 1 equiv. per each Mha group) was added to the solution. The overall mixture was 
shaken vigorously for 2 min to yield the target peptide. which was purified using semi-preparative 
HPLC and lyophilized to yield Ligand C. ESI-MS (m/z): 694.04 [M+3H]3+.  And calculated 2077.83 
g/mol. See SI for HPLC chromatograms. 
Physiochemical characterization of the ligands and their Fe(III) complexes 
General solutions preparation: 
For all titrations, deionized milli-Q water was used. A carbonate-free 0.1 M KOH solutions were freshly 
prepared and standardized against KHP (potassium hydrogen phthalate) primary standard before each 
experiment to find the exact concentration of KOH. HCl solutions (0.1 M) of were freshly prepared. 
EDTA2- solutions were prepared from EDTA.2Na salt and pre-standardized against MgSO4 standard 
solution at pH=10 to Eriochrome black T endpoint. Fe (III) solutions were freshly prepared using 
Fe(NO3)3.9H2O either in MeOH (for stoichiometric experiments) or in deionized water for the rest of 
experiments, and standardized against EDTA2- solution at pH=4 using salicylic acid as an indicator. 
UV-visible spectra were recorded over the range of 200-800 nm (unless other range is specified) against 
blank solutions of the same solvent and ionic strength of each sample. All physiochemical 
characterization experiments were done at room temperature. 
Ligand-Fe (III) complex stoichiometry determination  
A series of 13 solutions all containing 0.15 mM of Ligand A or Y in MeOH (0.05 mM in case of Ligands 
B and C), various volumes of standard Fe(III) solution in MeOH were added to each solution with 
Fe(III) to ligand ratios ranging between 0 and 0.6 for ligand A and Y, while ratios were ranging between 
0 and 2 for ligands B and C. 1.1 equivalents of 2,6-lutidine per ligand were added to all solutions. All 
solutions were made up to the same volume with methanol. UV-visible spectra for each solution were 
recorded. 
Determin tion of Lig n ’s proton tion  onstants (pKa) 
For each ligand, a 50.0 mL solution of 5.2 x 10-5 M at ionic strength equals 0.1 M of KCl was acidified 
with HCl standard solution to pH about 2. The solution was then stirred vigorously through the 
experiment and titrated against KOH solution over the pH range 2-11. Small additions of KOH could 
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raise the pH by around 0.3 unit, when the pH reading changed by <0.01 unit over 3 seconds, and 
equilibrium period for 1 minute started. Then pH reading, as well as UV-visible spectra, were recorded 
after each addition with a total of 20 addition. All titration data were analysed by KEV software and 
species diagrams were generated using Hyss software. 
Competition with EDTA 
A series of 10 solutions, all containing a constant amount of the corresponding Ligand (3.1 x 10-5 M, 
and 9.3 x 10-5 M for ligand A) and Fe(III) (3.0 x 10-5 M) in 0.5 % DMSO-water. Ionic strength in all 
was adjusted to be 0.1 M KCl, and various volumes of standard EDTA2- solution were added to each 
solution to make [EDTA2-] / [Fe3+] ratios ranging between 0 and 10. All solutions were made up to the 
same volume with water, shaken vigorously for 48 hrs. pH readings and UV-visible spectra for each 
solution were recorded after the equilibration time. 
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Abstract:  2019  has  been  an  excellent  year  in  terms  of  peptides  and  oligonucleotides  (TIDES) 
approved by the FDA. Despite the drop in the number of total drugs approved by the FDA in 2019 













Food  and Drug Administration  (FDA)  approved  a  total of 175 new drugs  for  commercialization 
(Figure 1) [1–4]. Forty‐eight drugs were approved  in 2019 [4], 10 of which were biologics and  the 













































































































This neutral backbone  confers greater  stability  to  the  strand  than  the natural negatively‐charged 
70
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is  a  progressive muscle  deterioration  that  starts  in  early  childhood  and  in most  cases  ends  up 
crippling patients before adolescence. After several years, patients die mainly from heart failure [7,8]. 






















in others  they are substituted by  the highly electronegative  fluorine atom  (2′‐F‐ribonucleoside)  in 
order to boost the stability of the double strands against the nuclease [16]. In addition, the hepatocyte‐
targeting ligand that is attached to the 3′ terminal of the sense strand has three N‐acetylgalactosamine 
moieties. The other  three  terminals  (5′ of  the sense strand, and 3′,5′ of  the antisense strand) have 
thiophosphate linkages in the last two subunits for each side. This conjugation (ESC‐GalNAc‐siRNA) 
confers  enhanced  stability  upon  subcutaneous  administration  of  the  siRNA  and  offers  a  10‐fold 
increased  potency  of  the  drug  over  the  standard  template  chemistry  (STC)  [13,17]. Givosiran  is 
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prepared as the sodium salt of a double‐strand oligonucleotide (sense and antisense strands) (Figure 
3) and it has a molecular weight of 17,245.56 Da.   
sense strand 5' CAG AAA GAG UGU CUC AUC UUA 3'



















































Givosiran was developed  for  the  treatment of  acute hepatic porphyria  in adults, which  is  a 
genetic disorder that results in the accumulation of the neurotoxic intermediates aminolevulinic acid 
(ALA)  and  porphobilinogen  (PBG)  during  the  hemes  production  cycle  (the  hemoglobin  oxygen 





thereby  halting  ALA  production  and  consequently  preventing  the  accumulation  of  the  toxic 
intermediates in body tissues [18]. 
Givosiran is administered subcutaneously and is well‐tolerated. However, regular check‐ups for 












towards  sstr  subtype  2  (sstr2)  is  about  10‐fold  that  of  68Ga‐DOTATOC  [24]. Nevertheless,  68Ga‐
DOTATOC  is  able  to  detect  more  NET  lesions  than  the  DOTATATE  analogue  with  highly 
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Figure 4. Chemical structure of 68Ga‐DOTATOC. 
A study by L. K. Khor et al. has shown  that 68Ga‐DOTATOC  is a good biomarker  for newly‐
diagnosed undifferentiated nasopharyngeal carcinomas (NPCs), and to a lesser extent for recurrent 
NPC and metastatic nodes [25]. 







pruritis, and  flushing  [26].  It was developed by  the University of  Iowa Health Care  (UIHC) and 
approved by  the FDA on 21 August 2019  [27]. From  the same  family,  in 2018  the FDA approved 
[177Lu]Lu‐DOTA‐TATE  ([[177Lu]Lu‐DOTA0,  Tyr3]‐octreotate)  for  the  treatment  of 
gastroenteropancreatic neuroendocrine tumors (GEP‐NETs) [28]. 
3.2. Afamelanotide (Scenesse®) 
Afamelanotide  is a synthetic  tridecapeptide  structural analogue of α‐melanocyte  stimulating 
hormone (α‐MSH) with a molecular weight of 1646.87 Da (Figure 5A) [29]. It differs from the natural 
analogue  (Figure  5B)  in  its  fourth  and  seventh  amino  acid  residues,  in which Met  and  Phe  are 
replaced by norleucine  (Nle) and D‐Phe,  respectively  [30]. Such modifications play a key  role  in 
enhancing the properties of afamelanotide versus the physiological α‐MSH analogue. In this regard, 
afamelanotide  shows  enhanced  resistance  against  enzymatic  degradation,  increases  biological 
activity, and prolongs the plasma half‐life [30] by stimulating binding affinity with melanocortin 1 
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cyclo[Asp‐His‐DPhe‐Arg‐Trp‐Lys]‐OH  [38].  The  cycle  through  an  amide  bond  is  between  the  ß 
carboxylic acid of Asp  ε amino of  the Lys, which  is  the C‐terminal  residue. The  exocyclic Nle  is 
acetylated. It has a molecular weight of 1025.182 Da. The structure is shown in Figure 6. 
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However,  increased  sexual desire  in patients was observed as a  side  effect  [44]. Later on,  it was 
developed by Palatin  technology  as  a  treatment  for HSDD  [44]  and  then out‐licensed  to AMAG 
PHARMS and approved by the FDA on 21 June 2019 [45]. 
Although bremelanotide  and  afamelanotide  belong  to  the  same α‐MSH hormone‐analogous 
family,  their  structures  show  some  differences.  Bremelanotide  resembles  the middle  section  of 
afamelanotide with the absence of the first three residues Ser‐Tyr‐Ser at the N‐terminus and the last 





transporting  cytotoxic  chemotherapeutic  agents  to  certain  tumors  [47]. This drug has  three main 
components:  payload/cytotoxic  drug,  mAb,  and  linker  [47].  The  antibody  comprises  human 
monoclonal antibody (enfortumab) and targets nectin‐4 (also known as poliovirus receptor‐related 













potent  microtubule‐disrupting  agent  [48].  It  is  a  structurally‐modified  analogue  of  the  natural 
dolastatin 10 [50], a potent antineoplastic pentapeptide (785.1 Da) isolated from the marine mollusk 
dolabella  auricularia by Pettit  et  al.  in  1987  [51]. MMAE  comprises  the  following  four  amino  acid 
residues: dolavaline  (Dov), Val, dolaisoleuine  (Dil), dolaproine  (Dap),  and  the C‐terminal  amine 
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Pharmaceuticals 2020, 13, 40  9  of  16 
The drug binds to nectin‐4‐expressing cells. The resulting complex is internalized into the cell 
and then the valine‐citruline (Val‐Cit) dipeptide linker is recognized and cleaved by cathepsin‐B in 
the  tumor cell  [57]. Consequently,  the cytotoxic MMAE  is selectively  released,  thereby  leading  to 
apoptosis [46]. 
It  is  administered  intravenously.  Common  adverse  effects  include  fatigue,  peripheral 
neuropathy, decreased appetite, rash, alopecia, nausea, dysgeusia, diarrhea, dry eye, pruritus, and 
dry skin [58]. 









Of  note,  the  tolerability  and  safety  profile  of  this  drug  was  accepted  for  non‐Hodgkin’s 
lymphoma (NHL) patients but not for those with chronic lymphocytic leukemia (CLL) [61]. 






The  choice  of  a  suitable  linker  is  a  highly  sensitive  step  in ADC manufacturing.  First,  the 
conjugate should be stable enough during its circulation  in blood serum to avoid damaging body 










antibody)  may  cause  the  loss  of  anticancer  activity  [65,66].  In  PadcevTM  and  PolivyTM,  a 
maleimidocarpoyl moiety is added to the N‐terminal of the dipeptide Val‐Cit to facilitate conjugation 
to the antibody. The amide bond formed by the C‐carboxyl group of the Cit, which is linked to a self‐
immolative  p‐amino  benzyl  carbamate  (PABC)  spacer,  is  stable  in  serum  and  can  be  rapidly 









The  ADC  fam‐trastuzumab  deruxtecan‐nxki  (EnhertuTM)  targets  human  epidermal  growth 
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Abstract: In 2018, the United States Food and Drug Administration (FDA) approved a total of 59 new
drugs, three of them (5%) are TIDES (or also, -tides), two oligonucleotides and one peptide. Herein,
the three TIDES approved are analyzed in terms of medical target, mode of action, chemical structure,
and economics.
Keywords: dotatate; drugs; inotersen; Lutathera; oligonucleotides; Onpattro; patisiran; peptides;
pharmaceutical market; Tegsedi
1. Introduction
Drug discovery is a unique transdisciplinary activity involving a wide range of interconnected
parameters, thus posing a challenge for the pharmaceutical industry and related fields. The mission of
this industry is to improve or restore health and wellbeing. Indeed, the administration of an appropriate
treatment can very often save lives. Although the pharmaceutical industry was devoted mainly to
research and development after the second world war, over the years economics has increasingly
gained relevance. Between 12 and 20 years can lapse from the time a discovery has been made in a
research laboratory and a product reaching the market, and this development pipeline carries with it
an associated cost of up to US $ 1–2 billion. What are the main reasons behind these long development
times and high costs? There is probably no single answer. However, the main causes can be attributed
to the increasingly stricter requirements of the corresponding agencies, mainly the federal Food and
Drug Administration (FDA) in the USA, and the European Medicines Agency (EMA) in Europe,
regarding toxicity and safety profiles, and the need for new drugs to show superior performance to
that of those already on the market.
Drugs can be roughly divided into two main categories, namely biologics and chemical entities, the
former being prepared by means of biotechnological techniques, and the latter by chemical synthesis.
Figure 1 shows the 127 new drugs approved by the FDA in the last three years (2016–2018) (59 in
2018), classified on the basis of chemical structure [1–6]. In this period, 36 biologics (17 in 2018) and 91
chemical entities (42 in 2018) were endorsed by the FDA. In the biologics field, the predominance of
monoclonal antibodies (mAbs) is remarkable (28 in 2016–2018, and 12 in just the last year). As chemical
entities, the so-called small molecules continue to account for a considerable proportion of new drugs.
Natural product-based drugs and TIDES (oligonucleo- and pep-TIDES) each represent approximately
Pharmaceuticals 2019, 12, 52; doi:10.3390/ph12020052 www.mdpi.com/journal/pharmaceuticals
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10% of new drugs [7]. Indeed, there are currently 14 drugs (10 in 2018) inspired in natural products,
and 13 TIDES (three in 2018) on the market.
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Although only one peptide received FDA approval in 2018—a significant drop from the previous
year in which six were approved—2018 has been extremely important for oligonucleotides, with two
approvals. In support of this statement, only six oligonucleotide drugs have received FDA approval to
date (three in 2016).
Herein, the three TIDES (one peptide and two oligonucleotides) with FDA approval are analyzed
in terms of therapeutic use, mode of action, and chemical structures.
2. Oligonucleotides
The two oligonucleotides in the 2018 harvest, patisiran (OnpattroTM) and inotersen (TegsediTM),
are prescribed for the treatment of polyneuropathy hereditary transthyretin mediated amyloidosis
(hATTR) in adults.
Transthyretin (TTR or TBPA) is a transport protein that carries the thyroid hormone, thyroxine
(T4), and the retinol-binding protein when it is bound to retinol (vitamin A) [8]. The liver is the main
secretor of TTR into the bloodstream, and the choroid plexus secretes it into the cerebrospinal fluid.
TTR is formed by four monomers of 127 amino acids, rich in β-sheet structures. Its final quaternary
structure is a result of the association of two dimers in a face to face arrangement, creating a central
channel that is responsible for two binding sites [8].
Individuals with hATTR show a mutation in the TTR gene, which in the protein is translated by
replacing Val for Met at position 30 [9]. The mutation leads to an altered TTR protein structure [10],
thus causing more dissociation at the dimer-dimer interface than in the wild-type. This dissociation
results in the accumulation of the misfolded protein as insoluble amyloid fibrils in multiple organs,
including nerves, heart, and gastrointestinal tract [11], and ultimately causes the disorder.
Previous treatments for this disease involved orthotopic liver transplantation (OLT) [10] and the
use of some drugs, such as tafamidis [12] and diflunisal [13]. These act as TTR protein stabilizers, and
thus delay the deposition of fibrils.
2.1. Patisiran (OnpattroTM)
The approval of patisiran (OnpattroTM) is probably the most impressive breakthrough in the drug
discovery field in recent years. Patisiran is a double strand small interfering RNA (siRNA). Formulated
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as patisiran sodium, and with a molecular weight of 14,303.6 Da, this drug is encapsulated within a
liposome nanoparticle for better delivery to the liver, where TTR is produced [14].
Patisiran is the first siRNA drug to use RNA interference (RNAi) to downregulate protein
expression. The RNAi pathway was first described in 1998 by Fire and Mello [15], who were awarded
the Nobel Prize in Medicine in 2006 for their work. Twenty years after the seminal publication,
approval for patisiran was granted to Alnylam Pharmaceuticals, Inc. [16]. Patisiran had previously
been granted Fast Track, Priority Review and Breakthrough Therapy, and Orphan Drug designations
to facilitate its final approval. Figure 2 shows the patisiran sequence.
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R= H  (oligodeoxiribonucleotide)
R= OCH2CH2OCH3 (2’-O-methoxyethyl-oligoribonucleotide analogue)Phosphorothioate
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Patisiran is administered intravenously once every three weeks, and it has a demonstrated average
knockdown of 87% and maximu of 96% of the TTR protein. Although, studies have shown that it
is relatively well tolerated, it can cause some side effects, including tract infections, infusion-related
reactions [13], and a decrease in vitamin A levels [13,17]. An important drawback of patisiran is the
high cost of the treatment, which is calculated to be approximately $450,000 [18].
2.2. Inotersen (TegsediTM)
Inotersen is a single stranded 20-mer phosphorothioate antisense oligonucleotide with 10 central
2′-deoxyribonucleotides flanked by five 2′-O-methoxyethyl ( OE)-modified ribonucleotides at each
of the 5′- and 3′-termini (5-10-5 gapmer structure) [19] (Figure 3). All pyrimidines (cytosine C and
uracil U) are 5-methylated, thereby increasing affinity for the complementary chain. Once inotersen is
hybridized to mRNA, the complex is degraded by RNaseH, reducing the total amount of TTR secreted
by the liver [20].
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I t i for ulated as odi m salt, with a molecular weight of 7600.8 Da [19]. Tegsedi was
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However, it does cause some side effects, such as abnormally low levels of platelets (thrombocytopenia)
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and abnormal renal function (glomerulonephritis) [20]. Treatment with inotersen has a similar cost to
that of patisiran [22].
2.3. Comments
Of the 59 drugs approved by the FDA in 2018, patisiran deserves to be named “Drug of the
Year”. It is an oligonucleotide, where only six have been approved to date by the FDA, it shows a
double strand, and requires a nanoformulation for its administration. From all points of view, patisiran
could be considered a “tour de force” or in another context a “piece of art”. However, the main
drawback is the investment needed for its development (some analysts are estimating this to be about
US $ 2 billion) and the cost of treatment (US $ 450,000) [18]. Taking into account that its target is the
same as that of inotersen, which has a similar treatment cost, these two drugs will compete for the
same market, and are therefore unlikely to make a return on investment.
3. Lutathera®
[177Lu]Lu-DOTA-TATE ([[177Lu]Lu-DOTA0, Tyr3]-octreotate) belongs to an emerging treatment
called Peptide Receptor Radionuclide Therapy (PRRT) [23]. PRRT involves the combination of a
chelating agent holding the radionuclide and a peptide, which binds to receptors overexpressed by
tumor cells. This mechanism facilitates localized treatment, and can therefore be considered a targeted
therapy. [177Lu]Lu-DOTA-TATE is the first PRRT to have received FDA approval. It contains 177Lu as
radionuclide and DOTA (also known as tetraxetan) as a chelator, the latter bound to [Tyr3]-octreotate
(Figure 4). This peptide is a strong somatostatin receptor antagonist that is overexpressed in tumor
cells [24]. The trivalent radiometal 177Lu has optimal β- and γ-emission characteristics, making it
suitable to be used in theranostic radiopharmaceuticals as compared with other radionuclides: 111In
for diagnostic and 90Y for therapy [25].
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[177Lu]Lu-DOTA-TATE is used for the treatment of gastroenteropancreatic neuroendocrine tumors
(GEP-NETs). It was developed by Advanced Accelerator Applications USA, Inc. and then approved
by the FDA in January 2018 [26].
In the case of PRRTs, as well as other similar radionuclide constructs used just for imaging, the
main challenge is to widen the use of targeting peptides beyond somatostatin analogs. Research efforts
should be channeled into more peptides from diverse families, with the aim of broadening the use of
this kind of therapy.
4. Conclusions
The three TIDES approved by the FDA in 2018 can be considered unique. [177Lu]Lu-DOTA-TATE
is the first drug of the PRRT family, patisiran is the first siRNA drug, and inotersen shows a distinctive
gapmer structure. The acceptance of these drugs undoubtedly paves the way for the authorization of
others with the same mode of action.
Finally, it is important to highlight that these and other drugs approved by the FDA in 2018
have a cost in the range of a six-digit figure, thus making them unaffordable for a large segment of
the population.
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Abstract: 2017 was an excellent year in terms of new drugs (chemical entities and biologics) approved
by the FDA, with a total of 46. In turn, one of the highlights was the number of peptides (six) included
in this list. Here, the six peptides are analyzed in terms of chemical structure, synthetic strategy used
for their production, source, therapeutic use, and mode of action.
Keywords: pharmaceutical market; drugs; drug discovery; solid-phase peptide synthesis
1. Introduction
The financial investment associated with the pharmaceutical industry is one of the largest in
the industrial sector—surpassed only by the telecommunications sector. However, the number of
new products (drugs) entering the market each year is relatively low. In this context, 2017 was an
exceptional year, in that 46 new drugs were approved by the US Food and Drug Administration
(FDA) [1]—the highest figure in the last twenty-five years. Drugs can be broadly divided into two main
groups. The first encompasses biologics (12 approved in 2017, accounting for 25% of the total number
of drugs approved), which are prepared by means of biotechnological techniques. The second group
comprises chemical entities (34 approved in 2017), which are prepared using chemical synthesis [2].
In turn, chemical entities can be grouped into two categories, the so-called small molecules, which also
include some natural products, and TIDES (peptides and oligonucleotides). Figure 1 shows the drugs
approved by the FDA in 2017 and classified on the basis of their chemical structure. Thus, in a
clockwise direction, biologics (antibodies, enzymes, and antibodies drug conjugates) appear first,
followed by peptides, modified amino acids, and more traditional small molecules.
Along a similar line, 2017 was an excellent year for peptides, with the FDA approving five
peptides and one peptidomimetic, which together accounted for 13% of the drugs accepted that year.
However, the 2017 figures should be interpreted with care. They cannot be taken as a trend since
the arrival of a drug onto the market involves many unpredictable variables.
From a structural point of view, the six peptides in the 2017 harvest show almost the full range
of diversity, probably lacking only a homodetic cyclic peptide and/or a cyclodepsipeptide. In this
regard, in addition to a peptidomimetic macimorelin (MacrilenTM), the 2017 harvest included two
linear peptides angiotensin II (GiaprezaTM) and abaloparatide (TymlosTM) with 8 and 34 amino
acids, respectively, and a peptide plecanatide (TrulanceTM) containing two disulphide bridges. It also
Pharmaceuticals 2018, 11, 42; doi:10.3390/ph11020042 www.mdpi.com/journal/pharmaceuticals
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included the following two unique branched peptides: semaglutide (OzempicTM) with a chain
pending at a Lys residue, which contains two mini-PEG amino acids, a Glu residue linked to the chain
through theω-carboxylic group, and a C18 diacid; and etelcalcetide (ParsabivTM), which is formed
by a linear chain of seven D-amino acids with a disulphide bridge between a D-Cys with a single
L-Cys. Interestingly, three of these peptides (macimorelin, abaloparatide, and semaglutide) contain a

































Figure 1. New drugs approved by the FDA in 2017 and classified on the basis of chemical structure.
Only one of these pe tides have been developed by two so-call d big phar as (semaglutide by
Novo Nordisk A/S) and the rest by biotech companies. Macimorelin had its roots in Fehrentz and
Marti ez’s group at the University of Montpellier (France). The five peptides other than macimorelin
were produced using the solid-phase technique.
2. Plecanatide (Trulance)
This peptide has a linear sequence of 16 amino acids with two disulphide bridges pairing Cys
4 with Cys12 and Cys7 with Cys15. Its C-terminal residue is in acid form (molecular weight of
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(molecular weight of 1048.3 Da), and it is manufactured using a solid‐phase technique (Figure 3). The 















Figure 2. Structure of (a) plecanatide and (b) the related linaclotide.
Plecanatide differs from uroguanylin (the endogenous counterpart of plecanatide) only in the
replacement of Asp3 by Glu3 [3].
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It was developed by Synergy Pharmaceuticals (New York City, NY, USA) and was approved by the
FDA on 7 January 2017 for the treatment of chronic idiopathic constipation (CIC) and irritable bowel
syndrome with constipation (IBS-C) [4]. Plecanatide is an agonist of guanylate cyclase-C, it increases
intestinal transit and fluid through a build-up of guanosine 3′,5′-cyclic monophosphate (cGMP) [5]
and has a similar mode of action as linaclotide (Constella-Linzess) (Figure 2b), which is a 14-amino
acid peptide containing three disulphide bridges which are located between Cys1 and Cys6, between
Cys2 and Cys10, and between Cys5 and Cys13. Linaclotide was approved by the FDA in 2012 [6].
Plecanatide draws water into the gastrointestinal (GI) tract, thereby softening stool and
encouraging its natural passage. It activates guanylate cyclase-C (GC-C) on endothelial cells within
the GI [7]. The pH-dependent activation of GC-C receptors by plecanatide (as it has the acidic residues
Asp2 and Glu3) may promote bowel movements without causing severe diarrhea [3,7]. Furthermore,
in molecular dynamics simulations, plecanatide showed optimal activity at pH 5, indicating that the
proximal intestine (pH 5–6) is the ideal site of action [8].
The activation of GC-C catalyzes the production of the second messenger cGMP, which leads to
the protein kinase A (PKA)- and protein kinase G II (PKGII)-mediated phosphorylation of the cystic
fibrosis transmembrane conductance regulator (CFTR) protein [9]. Upon activation, CFTR secretes
chloride (Cl−) and bicarbonate (HCO3−) into the GI tract lumen, followed by the passive secretion of
positively charged sodium ions into the lumen, and water follows by osmosis [10].
In the GI tract, plecanatide is metabolized by intestinal enzymes. The excretion of plecanatide has
not been studied in humans [3].
Plecanatide is administered orally as is linaclotide. These two examples showcase the feasibility
of the oral administration of peptides.
3. Etelcalcetide (Parsabiv)
This is an octapeptide formed by a linear chain of seven D-amino acids containing a D-Cys,
which is linked through a disulphide bridge to an L-Cys. The C-terminal residue is in amide
form (molecular weight of 1048.3 Da), and it is manufactured using a solid-phase technique
(Figure 3). The presence of amino acids in D configuration confers the peptide chain resistance
to proteolytic degradation. The presence of disulphide bonds facilitates the biotransformation process,
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Figure 3. Structure of etelcalcetide. ino acids of configuration are sho n in red.
Etelcalcetide was developed by KAI Pharmaceuticals Inc. (South of San Francisco, CA, USA),
a wholly subsidiary of Amgen Inc. (Thousand Oaks, CA, USA) and approved by the FDA on
7 February 2017 [14]. It is used for the treatment of secondary hyperparathyroidism (SHPT) in chronic
kidney disease (CKD) in adult patients on hemodialysis [11,12,15–18]. Cardiovascular calcination is
common in CKD patients, and it occurs as a result of impaired mineral homeostasis and secondary
hyperparathyroidism [16]. As a calcimimetic agent, etelcalcetide binds to the calcium-sensing receptor
(CaSR) through a disulphide bridge between the D-Cys of the etelcalcetide molecule and L-Cys of the
CaSRs, thereby enhancing activation of the receptor by means of extracellular calcium. Accordingly,
activation of CaSRs on parathyroid chief cells decreases the secretion of parathyroid hormone (PTH),
as well as fibroblast growth factor-23 (FGF23), which is stimulated by PTH [12,13,15–21]. Furthermore,
etelcalcetide decreases phosphorus in the blood. Interestingly, high blood phosphorus occurs in
vascular calcification [16].
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A serious side effect of etelcalcetide is that it reduces serum calcium levels, which might lead to
hypocalcemia. Therefore, monitoring serum calcium (after etelcalcetide dosing is initiated), as well as
PTH, is deemed necessary [13,15,21]. Etelcalcetide can cause vomiting and nausea [11,13,20,21].
4. Abaloparatide (Tymlos)
This is a linear C-terminal amide peptide that contains 34 amino acids. The C-terminal residue is in
amide form (molecular weight of 3960.7 Da) (Figure 4a). It is manufactured by a hybrid solution–solid
phase approach.
Abaloparatide can be considered a second generation teriparatide (Forteo) (Figure 4b), which is a
recombinant form of PTH (84 amino acids), formed by the N-terminal fragment (34 amino acids) of
PTH. Abaloparatide contains exactly the same number of amino acids as teriparatide but has multiple
substitutions. It has 41% homology with teriparatide [22]. Interestingly, abaloparatide has an Aib
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Figure 4. Structure of (a) abaloparatide and (b) teriparatide. The residues modified are shown in red.
The non-proteinogenic amino acid Aib is shown in bold.
Abaloparatide was developed by the biotech company Radius Health, Inc. (Waltham, MA, USA)
and approved by the FDA on 28 April 2017 [23].
Abaloparatide works as an anabolic (bone-growing) agent through the selective activation of
the parathyroid hormone 1 receptor (PTH1R), a G protein-coupled receptor (GPCR) expressed in
osteoblasts and osteocytes [22]. This receptor can be present in two distinct conformation states
(R0 and RG), which differ in their signaling response. Ligands that bind selectively to the RG state
result in a shorter signaling response, whereas those that bind selectively to the R0 state lead to a
prolonged response [24]. Abaloparatide preferentially binds to the RG state of PTH1R, which in turn
elicits a transient downstream cyclic AMP signaling response towards a more anabolic signaling
pathway [22,24].
Abaloparatide outperforms teriparatide as an anabolic agent, as shown by the increased messenger
ribonucleic acid (RNA) expression level for the receptor activator of nuclear factor kappa-B ligand
(RANKL) and macrophage colony-stimulating factor in a human osteoblastic cell line. Although the
molecular mechanisms underlying the differences between abaloparatide and teriparatide are not
well understood, they may be related to conformational differences that determine the affinities of the
drugs for PTHR1 [22].
5. Semaglutide (Ozempic)
Semaglutide contains a linear sequence of 31 amino acids, with a moiety pending from the ε-amino
function of Lys20 (the numeration of the amino acids in semaglutide is done by taking as reference the
numeration in the parent peptide GLP-1), which contains a Glu residue linked to the ε-amino group of
Lys side-chain through the γ-carboxylic group, two mini-PEG amino acids [8-amino-3,6-dioxaoctanoic
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acid (ADO)] and a C18 diacid (Figure 5a). The C-terminal is in the form of a carboxylic acid (molecular
weight of 4113.6 Da). It is manufactured using a solid-phase approach.
Semaglutide is a member of the glucagon like peptide-1 (GLP-1) family, derived from the GLP-1
(sequence 7-37), and can be considered the second generation of liraglutide (Figure 5b), which was
accepted by the FDA in 2010 [25]. Liraglutide differs from GLP-1 (7-37) (Figure 5b) in the presence
of Arg in position 34 instead of Lys and of a moiety at Lys20, which is a reduced version of the one
in semaglutide. When comparing the structures of semaglutide and liraglutide, in addition to the
pending moiety, semaglutide has Aib instead of Ala in position 8, thereby reducing the susceptibility
of semaglutide to degradation by dipeptidyl peptidase-4 [26–28]. Both semaglutide and liraglutide
were developed by Novo Nordisk A/S (Måløv, Denmark). Semaglutide was approved by the FDA on
21 December 2017 [29].
Pharmaceuticals 2018, 11, x  5 of 10 
 
3,6‐dioxaoctanoic  acid  (ADO)]  and  a C18 diacid  (Figure  5a). The C‐terminal  is  n  the  form  of  a 
carboxylic acid (molecular weight of 4113.6 Da). It is manufactured using a solid‐phase approach. 
             li   ti ‐  ( ‐ ) fa ily, derived from the GLP‐
1 (sequence 7‐37), and can be considered the second generation of liragl ti  ( i        
   t e F  in 2010 [25]. Liraglutide differs from GLP‐1 (7‐37) (Figure 5b) in the presence of 
Arg in position 34 instead of Lys and of a moiety at Lys20, whic  is a reduced version of the one in 
semaglutide. When  comparing  the  structures  of  semaglutide  and  liraglutide,  in  addition  t    
  ,                           
            ‐            















Figure 5. Structure of (a) semaglutide and (b) its related liraglutide. Changes in structure with respect
to GLP-1 (7-37) are shown in color.
The GLP-1 family stimulates insulin and decreases glucagon secretion. However, GLP-1 has a
short half-life (1–2 min) as a result of proteolytic degradation, thus hindering its use as a potential
treatment for type 2 diabetes [27]. Liraglutide is the first once-daily glucagon-like peptide-1 analogue
designed to resist enzymatic degradation and thus have a longer half-life [26,27,30]. The presence
of the 17-carboxyheptadecanoyl fatty acid moiety results in its binding to human albumin, which is
responsible for the longer-acting activity of liraglutide in comparison with other members of the same
family. The rationale behind the design of semaglutide, which allows once-weekly administration,
is to increase the affinity of the pending fatty acid moiety for albumin. Moreover, semaglutide has no
serious adverse effects, only some mild gastrointestinal disorders [27].
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6. Macimorelin (Macrilen)
Macimorelin is a small pseudopeptide formed by three residues: Aib as N-terminus, D-Trp at
the central position, and a mimetic of D-Trp—a gem diamino moiety—which is formylated at its
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Diego, CA, USA), and approved by  the FDA on 21 December 2017  [38].  It  is  recommended as a 
vasoconstrictor  to  increase  blood pressure  in  adults with  septic  or  other distributive  shock.  It  is 
administered intravenously because its half‐life is approximately 30 s. 
Angiotensin  II  is  related  to  the  renin–angiotensin  System  (RAS).  From  a  drug  discovery 
perspective, it can be considered unique among the drugs approved by the FDA in recent years. Its 
roots can be found in the last part of the XIX century, when Tigerstedt and Bergman discovered the 
effect  of  renal  extracts  on  arterial  pressure  [39].  In  the  1930s,  two  independent  groups,  one  in 
Argentina with  Leloir, Houssay,  Fernandez  Braun,  among  others,  and  that  of  Page  in  the  US, 
discovered that RAS is the hormone system that regulates blood pressure and fluid balance [40]. In 
1957, again two groups—one in the US (Schwarz and colleagues) [41] and the second in Switzerland 
(GIBA  Geigy)  [42]—described  the  first  synthesis  of  angiotensin  II.  Seventy  years  after  its  first 
synthesis, this octapeptide reached the market.   
Angiotensin II is formed after the removal of two C‐terminal residues of angiotensin I by the 
angiotensin‐converting  enzyme  (ACE).  In  turn,  angiotensin  I  is  the  N‐terminal  part  of 
angiotensinogen, an α‐2‐globulin produced constitutively and released into the circulation mainly by 
the liver 
Figure 6. Structure of macimorlein. Modifications with respect to a tripeptide are shown in red.
Macimorelin was discovered by Fehrentz and Martinez’s group at the University of Montpellier [31]
and developed by the biotech company Aeterna Zentaris GmbH (Frankfurt, Germany). It was approved
by the FDA on 20 December 2017 [32]. Administered orally, it is used for the diagnosis of adult growth
hormone deficiency (AGHD).
Macimorelin acts as a growth hormone secretagogue (GHS) mimicking ghrelin, which is a
28-amino acid peptide produced by the stomach and is the endogenous ligand for this GHS
receptor [31,33–36]. In addition to being orally bioavailable, macimorelin is selective, tolerable, and also
safe, with only mild adverse effects—such as an unpleasant taste—being reported [34,35,37].
By acting in an almost identical manner to ghrelin [37], macimorelin outperforms other GHS such
as the expensive recombinant human GH.
7. Angiotensin II (Giapreza)
Angiotensin II is a simple linear octapeptide formed by natural amino acids of the L series
and its structure is identical to the human hormone of the same name. The C-terminal is in the
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administered intravenously because its half‐life is approximately 30 s. 
Angiotensin  II  is  related  to  the  renin–angiotensin  System  (RAS).  From  a  drug  discovery 
perspective, it can be considered unique among the drugs approved by the FDA in recent years. Its 
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effect  of  renal  extracts  on  arterial  pressure  [39].  In  the  1930s,  two  independent  groups,  one  in 
Argentina with  Leloir, Houssay,  Fernandez  Braun,  among  others,  and  that  of  Page  in  the  US, 
discovered that RAS is the hormone system that regulates blood pressure and fluid balance [40]. In 
1957, again two groups—one in the US (Schwarz and colleagues) [41] and the second in Switzerland 
(GIBA  Geigy)  [42]—described  the  first  synthesis  of  angiotensin  II.  Seventy  years  after  its  first 
synthesis, this octapeptide reached the market.   
Angiotensin II is formed after the removal of two C‐terminal residues of angiotensin I by the 
angiotensin‐converting  enzyme  (ACE).  In  turn,  angiotensin  I  is  the  N‐terminal  part  of 
angiotensinogen, an α‐2‐globulin produced constitutively and released into the circulation mainly by 
the liver 
Figure 7. Structure of angiotensin II.
Angiotensin II was developed by a biotech company, La Jolla Pharmaceutical Comp ny
(San Diego, CA, USA), nd approved by the FDA on 21 December 2017 [38]. It is recommended
s a vasoconstrictor to increas blood pressure in adults with septic or other distributive shock. It is
administered intravenously because its half-life is approximately 30 s.
Angiotensin II is relat d to the renin–angiotensin System (RAS). From a drug discovery
perspective, it can be considered unique among the drugs approved by the FDA in recent years.
Its roots can be found in the last part of the XIX century, when Tigerstedt and Bergman discovered
the effect of renal extracts on arterial pressure [39]. In the 1930s, two independent groups, one in
Argentina with Leloir, Houssay, Fer andez Braun, among others, and that of Page in the US, discovered
that RAS is the hormone system that regulates bloo pressure and fluid balance [40]. In 1957, again
two groups—one in the US (Schwarz and colleagues) [41] and the second in Switzerland (GIBA
Geigy) [42]—described the first synthesis of angiotensin II. Seventy years after its first synthesis,
this octapeptide reached the market.
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Angiotensin II is formed after the removal of two C-terminal residues of angiotensin I by the
angiotensin-converting enzyme (ACE). In turn, angiotensin I is the N-terminal part of angiotensinogen,
an α-2-globulin produced constitutively and released into the circulation mainly by the liver.
As a summary, Table 1 shows the six peptides approved by the FDA in 2017 highlighting several
parameters (chemical modification, source, therapeutic use, mode of action, and administration) that
have been key to their development.
Table 1. Summary of the peptides approved by the FDA in 2017.
Generic Name











Activation of CaSR on
parathyroid chief cells
Secondary hyperpara-thyroidism
in adult patients with chronic
kidney disease on hemodialysis
IV
Abaloparatide






(Ozempic) Novo Nordisk, Inc.
Acts as a Glucagon-like
Peptide-1 agonist
Treatment of type 2
diabetes mellitus SC
Macimorelin




For the diagnosis of adult growth
hormone deficiency Oral
Angiotensin II
(Giapreza) La Jolla Pharm Co.
Acts on the CNS
to increase
ADH production
Control of blood pressure in
adults with sepsis or other
critical conditions
IV
* Wholly owned subsidiary of Amgen, Inc.; IV: intra venous; SC: subcutaneous.
Finally, it is important to recall the trend of the peptide market. This market was worth
US$5.3 billion in 2003, rising to US$8 billion in 2005 and US$14.1 billion in 2011, and it is expected to
reach a value of US$25.4 billion and US$46.6 billion by the end of 2018 and 2024, respectively [43–45].
Furthermore, there are currently hundreds of peptides in preclinical testing stages and around
150 peptides in clinical development. Many of these molecules are showing a promising therapeutic
impact [36,43,46–48].
It is to be hoped that the coming years will bring about the approval of a similar number of
peptides to those accepted by the FDA in 2017 and that the trends of the market in terms of peptide
development continue, thus making these molecules one of the best options to treat many diseases.
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Chapter 8. Conclusion and Future Perspectives 
Here we have introduced the synthesis of 1,2-HOPO containing peptides on solid support. The peptide 
backbones were synthesized using the standard SPPS Fmoc/tBu strategy and all were having Lys 
residues to hold the HOPO chelating moieties. The 1,2-HOPO-4-COOH (or 1,2-BnOPO-4-COOH) was 
introduced via two routes, through an amide linkage to the ε-NH2 of the Lys residues on the backbone. 
The use of the unprotected N-OH in HOPO succeeded in giving the desired product in good yields and 
purities. Also in case of using the benzyl protected HOPO in the synthesis, cleaving the peptide from 
resin by using the mixture TFA:TFMSA:TIS (8:3:1) resulted successfully in the removal of the benzyl 
protecting group in the same step. The second route was by conjugating two pre-synthesized peptides, 
one of them contain the 1,2-HOPO unit as well as a thiol function and the other having three maleimide 
moieties. Both synthetic routes allowed the preparation of 1,2-HOPO-peptides in good yields and 
purities. 
On the other hand, spectrophotometric evaluation the thermodynamic constants of the bidentate ligands 
(Y and A) and their Fe(III) complexes showed that they were comparable to those reported in literature. 
Which gives an indication that the position of the carboxyl substituent on the pyridine ring has less 
effect on the overall stability of the complex, with pFe+3 about 14.59 and 14.19. 
 The hexadentate ligands B and C formed 1:1 complex with iron stable enough to stand against the well-
known strong chelator EDTA at pH=7.4, with pFe+3 26.91 and 28.58, respectively. The strongest ligand 
was the hexadentate (ligand C) with slightly higher formation constant than that of (ligand B). Making 
these two potent candidates to be used as biostatic agents, since for an ideal agent pFe+3 >20 is required. 
Finally, this type of easily synthesized chelators (peptide-HOPO combinations) can be used not only 
for Fe (III) chelation but can also be used for other hard metal ions by tuning the denticity to fulfil the 
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Chapter 2. Solid-Phase Synthesis of Peptides Containing 1-Hydroxypyridine-2-one (1,2-
HOPO) 
Danah Al Shaer a,b, Fernando Albericiob,c,d  and Beatriz G. de la Torrea  
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KwaZulu-Natal, Durban 4001, South Africa; cInstitute for Advanced Chemistry of Catalonia (IQAC-
CSIC), 08034 Barcelona, Spain; cCIBER-BBN, Networking Centre on Bioengineering, Biomaterials 





Analytical HPLC: Agilent 1100 system using a Phenomex Luna C18 (3 μm, 4.6 × 150 mm) column, 
with flow rate of 1.0 mL/min, 30  ͦC, and UV detection at 220 nm. Buffer A: 0.1% TFA in H2O; buffer 
B: 0.1% TFA in CH3CN.  
LCMS:  
1) Shimadzu 2020 UFLC-MS.  Buffer A: 0.1% formic acid in H2O; buffer B: 0.1% formic acid in 
CH3CN, Flow: 1.0mL/min., UV detection=220 nm, Column: YMC-TriartC18 (5 μm, 4.6 × 150 mm) 
column, 30  ͦC. 
2) Thermo Scientific™ UltiMate™ 3000 Standard Binary System, ISQ™ EC Single Quadrupole.  
Buffer A: 0.1% formic acid in H2O; buffer B: 0.1% formic acid in CH3CN, Flow: 1.0mL/min., UV 
detection=220 nm, Column: Phenomenex Luna C18 3.6 μm, 4.6 × 150 mm column, 30  ͦC. 





Figure S2: MS (LCMS 1) for Ac-FKA-NH2.   
 
Figure S3:  MS (LCMS 1) for unprotected 1,2-HOPO-4-COOH incorporated into Ac-FKA-NH2.  

















Figure S3 A,B,C,D Full integrated chromatograms of Figure 2 in manuscript, Method 5-95% B in A 





1) HOPO/DIC 1:1 (1.5 eq) 
2)  20% Piperidine in DMF 
1) HOPO/DIC/Oxyma 1:1:1.3 (1.5eq) 
2) 20% Piperidine in DMF 
1) HOPO/DIC/Oxyma 1:1:1.3 (1.5 eq) 
2) HOPO/DIC/Oxyma 1:1:1.3 (0.75 eq) 
1) HOPO/DIC/Oxyma 1:1:1.3 (1.5 eq) 
2) HOPO/DIC/Oxyma 1:1:1.3 (0.75 eq) 


















Figure S6.  Expanded Figure 3 (main manuscript). Comparison of the HPLC crudes after the 
incorporation of unprotected 1,2-HOPO-4-COOH to Ac-K-K-K-S(tBu)-S(tBu)-resin.  Method 0-50% 

















Figure S6 A-B-C: Full integrated chromatograms in Figure 3 in manuscript, Method 0-50% B in A 





1) HOPO/DIC 1:1 (1.5 eq / Lys) 
2)  20% Piperidine in DMF 
1) HOPO/DIC 1:1 (1.5 eq / Lys) 
2) HOPO/DIC 1:1 (0.33 eq / Lys) 
3) 20% Piperidine in DMF 
1) HOPO/DIC 1:1 (1.5 eq / Lys) 
2) HOPO/DIC 1:1 (0.75 eq) 




Figure S7: MS (LCMS 2) for unprotected 1,2-HOPO-4-COOH incorporated into Ac-KKKSS-NH2.  
The 1,2-HOPO-4-CO- moiety could be incorporated in any of the three Lys.  HPLC, Figure 3, peaks 
around 4.5 min, main manuscript 
 
 
Figure S8: MS (LCMS 2) for two unprotected 1,2-HOPO-4-COOH incorporated into Ac-KKKSS-
NH2.  The 1,2-HOPO-4-CO- moieties could be incorporated into any of the three Lys.  HPLC, Figure 
3, peaks around 5.7 min, main manuscript 
 
Molecular Weight: 754,84 




Figure S9: MS (LCMS 2) for three unprotected 1,2-HOPO-4-COOH incorporated into Ac-KKKSS-
NH2.  HPLC, Figure 3, peak at 6.5 min, main manuscript 
 
 
Figure S10: HPLC chromatograms (Method 0-50% B in A over 15 min) for different conditions of 
incorporation of unprotected 1,2-HOPO-4-COOH on Ac-KKKSS-resin. All the couplings were carried 
out using 1.5 eq of 1,2-HOPO-4-COOH per Lys residue 






B) in DMF-CH3CN (1:1) at room temperature, 4 hrs. 
 
 
Figure S11 MS (LCMS 1) for one protected 1,2-HOPO-4-COOH incorporated into Ac-KKKSS-NH2.  
The protected 1,2-HOPO-4-CO- moiety could be incorporated in any of the three Lys.  HPLC, Figure 

















Figure S12 MS (LCMS 1) for two protected 1,2-HOPO-4-COOH incorporated into Ac-KKKSS-NH2.  
The protected 1,2-HOPO-4-CO- moieties could be incorporated in any of the three Lys.  HPLC, Figure 




Figure S13 MS (LCMS 1) for three protected 1,2-HOPO-4-COOH incorporated into Ac-KKKSS-NH2. 






















Figure S14: Comparison between Figure 3-C (using unprotected HOPO). figure 4-B (using protected 
HOPO then deprotection) in manuscript, Method 0-50% B in A over 15 min. (The slight shift of 
retention time is because using another HPLC instrument with all other conditions are the same) 










Using unprotected HOPO then cleavage 
with TFA:TIS:H2O (95:2.5:2.5) 
Using Bzl protected HOPO then Cleavage 




Chapter 4. Synthesis of new peptide-based Ligands with 1,2-HOPO pendant chelators 
and the thermodynamic evaluation of their iron (III) complexes 
 
General:  
Analytical HPLC: Agilent 1100 system using a Phenomex Luna C18 (3 μm, 4.6 × 150 mm) column, 
with flow rate of 1.0 mL/min, 30  ͦC, and UV detection at 220 nm. Buffer A: 0.1% TFA in H2O; buffer 
B: 0.1% TFA in CH3CN.  
LCMS:  
Thermo Scientific™ UltiMate™ 3000 Standard Binary System, ISQ™ EC Single Quadrupole.  
Buffer A: 0.1% formic acid in H2O; buffer B: 0.1% formic acid in CH3CN, Flow: 1.0mL/min., UV 
detection=220 nm, Column: Phenomenex Luna C18 3.6 μm, 4.6 × 150 mm column, 30  Cͦ. 
 














Figure S3: HPLC chromatogram for Ac-K(Mha)-K(Mha)-K(Mha)-ßA-NH2. Method 25-45% B in A 











































Figure S7: UV-visible spectra of Fe-L solutions in methanol around the chosen wavelength for 
stoichiometry determination for ligands: a) Y b) A c) B d) C. The highlighted spectra are for the 




Figure S8: Dependence of UV spectra on pH (I=0.1 M KCl) of 5.2 x 10-5 M solutions of a) Ligand Y, 
b) Ligand A, c) Ligand B, and d) Ligand C. Full spectra of Fig. 5 (main text)
 
   
   
   
                  
 
               
 
   
   
   
   
   
   
               
 
               
   
   
   
                  
 
               
   
   
   
                  
 
               
   
   
   
   
   
   
                     
 
               
   
   
   
   
   
   
                     
 
               
   
   
   
   
   
   
                     
 
               
   
   
   
   
   
                     
 
               
    
    
